皮膚科診療Controversy

出版社： 中外医学社
著者：
発行日： 2022-06-10
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784498063808
電子書籍版： 2022-06-10 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

10,780 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

10,780 円(税込)

購入する

商品紹介

皮膚科でみる様々な疾患の診断・治療についてエキスパートはどう考え，どう対応するか1問1答形式で伝授．「薬疹とウィルス疹の鑑別は？」「特発性蕁麻疹はなぜ起こる？」「老人性色素斑が脂漏性角化症になる？」「脂腺増殖症はなぜ加齢してから起こる？」「肝斑のレーザー治療は無意味か?」など明日からの臨床ですぐに役立つ実践的知識が満載の必読書．どこから読んでも興味深く，「なるほど！」と唸ること間違いなし！

目次

  • 診断をめぐるControversy
    　　1　ダーモスコピーで足底の色素斑は鑑別できるか？
    　　2　基底細胞癌はダーモスコピーで診断できる？
    　　3　ダーモスコピーで疥癬虫はみつけられるか？
    　　4　パッチテストパネルは有用か？
    　　5　イムノクロマト法は単純疱疹・帯状疱疹鑑別に有用か？
    　　6　水疱のない皮疹で水痘帯状疱疹ウイルス抗原検出キットは使えるか？
    　　7　悪性黒色腫の生検は禁忌か？
    　　8　検査を行うべき蕁麻疹は？
    　　9　内臓悪性腫瘍を調べるべき皮膚疾患は？
    　　10　自己抗体検査で皮膚筋炎の予後判定は可能か？
    　　11　乾癬性関節炎は皮膚科医でも診断できる？
    　　12　頬部に紅斑があればすべて蝶形紅斑か？
    　　13　Palmar hyperlinearityとは具体的にどういう手の小じわ？
    　　14　どういうとき重症薬疹への進展を疑う？
    　　15　白癬は見た目で診断できるのか？
    　　16　Rheumatoid vasculitisと関節リウマチに合併したほかの血管炎はどう区別する？
    　　17　薬疹とウイルス疹の鑑別は？
    　　18　血栓性静脈炎と蜂窩織炎の鑑別は？
    　　19　足底疣贅と鶏眼の鑑別は？

    病態をめぐるControversy
    　　20　汗疱・異汗性湿疹：金属アレルギーはどのくらい関与しているのか？
    　　21　異汗性湿疹は汗と関連するのか？
    　　22　掌蹠膿疱症に金属アレルギーは関与しているのか？
    　　23　保湿でアトピー性皮膚炎の発症は減らせるか？
    　　24　アトピー性皮膚炎における血清IgE高値は原因か？　結果か？
    　　25　特発性蕁麻疹はなぜ起こる？
    　　26　多形慢性痒疹とは本当はどういう疾患か？
    　　27　結節性痒疹はまったく掻破しなくても新生するのか？
    　　28　色素性蕁麻疹とびまん性肥満細胞症は別の病気か？
    　　29　老人性色素斑が脂漏性角化症になる？
    　　30　ほくろは悪性黒色腫になることはないのか？
    　　31　脂腺増殖症はなぜ加齢してから起こる？
    　　32　タクロリムス軟膏も酒皶を誘発するか？
    　　33　痤瘡は食べ物の影響を受けるのか？
    　　34　痤瘡桿菌（アクネ菌）の抗菌薬耐性化は進行しているのか？
    　　35　ステロイド痤瘡はマラセチア毛包炎か？　ケトコナゾールは有用か？
    　　36　化膿性汗腺炎は感染症か？
    　　37　敏感肌とは皮膚科学的にどういう状態なのか？

    治療をめぐるControversy
    　アトピー性皮膚炎
    　　38　プロアクティブ療法は有用か？
    　　39　デュピルマブの適応となる患者は？
    　　40　デュピルマブはいつ止められるのか？
    　　41　デュピルマブでアトピー性皮膚炎の寛解維持を図ることは妥当か？　
    　　42　デルゴシチニブ軟膏の利用価値の高い使い方は？
    　　43　アトピー性皮膚炎に生じたカポジ水痘様発疹症の皮疹にステロイド外用は禁忌か？
    　　44　アトピー性皮膚炎の寛解導入で血清TARC値は基準値以内にしなければいけないのか？
    　　45　脂漏性皮膚炎の発症に真菌は関与しているのか，ケトコナゾールは効くのか？
    　　46　皮脂欠乏症：保湿剤はどこまで有用か？　
    　蕁麻疹
    　　47　抗ヒスタミン薬は増量か変更か？
    　　48　特発性蕁麻疹では症状消失後どのくらい抗ヒスタミン薬を内服すればよいのか？
    　　49　蕁麻疹に外用は有効か？
    　　50　オマリズマブはなぜ原因がないはずの特発性慢性蕁麻疹に効果があるのか？　
    　　51　手足症候群の治療は？
    　膠原病
    　　52　ステロイド投与の対象となる強皮症は？
    　　53　抗MDA5抗体陽性の皮膚筋炎は間質性肺疾患がまったくなくても強力な治療を要するのか？　
    　　54　好酸球性膿疱性毛包炎の第一選択薬は？
    　乾癬
    　　55　乾癬に対する生物学的製剤の使い分けは？
    　　56　妊娠する可能性のある女性乾癬患者に投与するべき生物学的製剤は？
    　　57　生物学的製剤でPASIクリアを達成した後に生物学的製剤は止められるか？
    　　58　アプレミラストの効果が高いのはどういう乾癬？
    　　59　乾癬にも保湿は有効？
    　肝斑
    　　60　肝斑のレーザー治療は無意味か？
    　　61　肝斑にトラネキサム酸とビタミンCは有効なのか？
    　痤瘡
    　　62　尋常性痤瘡の初診患者の第一選択薬は？
    　　63　尋常性痤瘡に抗菌薬内服の適応はあるか？
    　　64　胸部や背部の痤瘡のよい治療法はあるか？
    　酒皶
    　　65　酒皶にメトロニダゾールは有効か？
    　毛髪疾患
    　　66　円形脱毛症の第一選択治療はステロイド局注か？
    　　67　男性型脱毛症の第一選択薬は？
    　　68　フィナステリドやデュタステリド内服にミノキシジル外用の上乗せ効果はあるか？
    　　69　女性のびまん性脱毛症のよい治療は？
    　爪疾患
    　　70　陥入爪の第一選択治療は？
    　　71　巻き爪は矯正治療後に元に戻らないのか？
    　良性腫瘍
    　　72　乳児血管腫の第一選択薬はプロプラノロール？
    　　73　乳児血管腫に対するレーザー治療はもう不要か？
    　　74　肥厚性瘢痕・ケロイドの切除は禁忌？
    　悪性腫瘍
    　　75　多発日光角化症の第一選択は？
    　　76　乳房外パジェット病はskip lesionや腋窩などの同時多発病変のすべての切除が必要か？
    　　77　どういうメラノーマにニボルマブ（オプジーボ）が奏効するか？
    　　78　悪性黒色腫のセンチネルリンパ節転移が陽性の場合，リンパ節郭清は必要か？
    　　79　BRAF変異のある進行期悪性黒色腫にはキナーゼ阻害薬と
    　　　　　免疫チェックポイント阻害薬をどのように選択すればよいか？
    　帯状疱疹
    　　80　帯状疱疹の初期治療はアメナメビルで十分か？
    　　81　帯状疱疹ワクチンは打つべきか？
    　　82　皮疹のない片側性の疼痛で帯状疱疹の可能性は？　治療は？
    　　83　妊婦や授乳婦に帯状疱疹の抗ヘルペスウイルス薬は使用できるか？
    　　84　帯状疱疹は抗ヘルペスウイルス薬の外用が必要か？
    　ウイルス感染症
    　　85　単純ヘルペスにPIT（patient—initiated therapy）は有用か？
    　　86　足底疣贅に凍結療法は効くのか？
    　　87　伝染性軟属腫は取るべきか？
    　細菌感染症
    　　88　MRSAによる伝染性膿痂疹の治療は？
    　　89　伝染性膿痂疹に抗菌薬治療に加えステロイド外用薬併用は害か？　有用か？
    　　90　伝染性膿痂疹にゲンタマイシン軟膏は意味があるか？
    　　91　深部静脈血栓症のある難治性蜂窩織炎に弾性包帯は禁忌か？
    　　92　梅毒治療の第一選択はいまでもペニシリン？
    　白癬
    　　93　白癬にステロイド外用は禁忌か？
    　　94　爪白癬に外用薬は効くのか？　いつまで続けるのか？
    　　95　爪白癬にホスラブコナゾールとテルビナフィンをどう使い分けるのか？
    　　96　頭部白癬に外用療法は意味があるのか？
    　　97　高齢者に経口抗真菌薬は使えないのか？
    　動物性皮膚疾患
    　　98　ピレスロイド抵抗性アタマジラミの治療は？
    　　99　疥癬治療は外用よりイベルメクチン内服？
    　薬剤／治療法
    　　100　保湿剤とステロイド外用はどちらを先に塗るべきか？　どちらでもよいのか？
    　　101　皮膚疾患でNSAIDs外用薬が本当に有効な疾患はあるのか？
    　　102　リンデロン®—VG軟膏のゲンタマイシンに意味はあるのか？
    　美容
    　　103　飲む日焼け止めの効果は？
    　　104　食べたコラーゲンは本当に皮膚に届くのか？　塗ったコラーゲンは真皮に入るのか？
    　　105　しわにフィラーは有用か？

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

診断をめぐるControversy

P.3 掲載の参考文献
1) Saida T, Koga H, Uhara H. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol. 2011 ; 38 : 25-34.
PubMed
2) Minagawa A, Omodaka T, Okuyama R. Melanomas and mechanical stress points on the plantar surface of the foot. N Engl J Med. 2016 ; 374 : 2404-6.
PubMed
3) Mikoshiba Y, Minagawa A, Koga H, et al. Clinical and histopathologic characteristics of melanocytic lesions on the volar skin without typical dermoscopic patterns. JAMA Dermatol. 2019 ; 155 : 578-84.
PubMed
4) 斎田俊明, 宇原久, 古賀弘志. ダーモスコピーのすべて 改訂第2版. 南江堂 ; 2021. p.99.
 
P.9 掲載の参考文献
1) Asgari MM, Moffet HH, Ray GT, et al. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015 ; 151 : 976-81.
PubMed
2) Ishihara K, Saida T, Otsuka F, et al. Statistical profiles of malignant melanoma and other skin cancers in Japan : 2007 update. Int J Clin Oncol. 2008 ; 13 : 33-41.
PubMed
3) Tamaki T, Dong Y, Ohno Y, et al. The burden of rare cancer in Japan : application of the RARECARE definition. Cancer Epidemiol. 2014 ; 38 : 490-5.
PubMed
4) 石井良征, 塩野昌行, 藤澤康弘, 他. 基底細胞癌の全国調査. Skin Cancer. 2013 ; 28 : 205-11.
 
5) Gloster HM, Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006 ; 55 : 741-60.
PubMed
6) 石原和之. 基底細胞癌 全国アンケートの集計と説明. Skin Cancer. 1994 ; 9 : 80-3.
 
7) Menzies SW, Westerhoff K, Rabinovitz H, et al. Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol. 2000 ; 136 : 1012-6.
PubMed
8) Marghoob AA, Braun R. Proposal for a revised 2-step algorithm for the classification of lesions of the skin using dermoscopy. Arch Dermatol. 2010 ; 146 : 426-8.
PubMed
9) 帆足俊彦, 石川雅士, 上原治朗, 他. 皮膚悪性腫瘍診療ガイドライン 第3版 基底細胞癌診療ガイドライン 2021. 日皮会誌. 2021 ; 131 : 1467-96.
 
10) 朱樹李, 宮地秀明, 丸裕吾, 他. 有棘細胞癌との鑑別を要した無色素性基底細胞癌11例の検討. 日皮会誌. 2021 ; 131 : 517-23.
 
11) Lallas A, Apalla Z, Argenziano G, et al. The dermatoscopic universe of basal cell carcinoma. Dermatol Pract Concept. 2014 ; 4 : 11-24.
PubMed
12) Cerci FB, Kubo EM, Werner B, et al. Dermoscopy accuracy for lateral margin assessment of distinct basal cell carcinoma subtypes treated by Mohs micrographic surgery in 368 cases. Int J Dermatol. 2021 ; May 20. doi : 10.1111/ijd.15655. Online ahead of print.
 
13) Tschandl P, Codella N, Akay BN, et al. Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification : an open, web-based, international, diagnostic study. Lancet Oncol. 2019 ; 20 : 938-47.
PubMed
P.11 掲載の参考文献
1) 日本皮膚科学会疥癬診療ガイドライン策定委員会. 疥癬診療ガイドライン (第3版). 日皮会誌. 2015 ; 125 : 2023-48.
 
2) 和田康夫. 疥癬虫の生態から学ぶ検出法. Derma. 2005 ; 101 : 51-6.
 
3) 和田康夫. 疥癬入門 基礎編. 医事新報. 2013 ; 4632 : 67-70.
Medical*Online
P.17 掲載の参考文献
1) Ito A, Suzuki K, Matsunaga K, et al. Patch testing with the Japanese Baseline Series 2015 : a 4-year experience. Contact Dermatitis. 2022 ; 86 : 189-95.
 
2) 伊藤明子. 接触皮膚炎～身近な化粧品による皮膚障害～. infoAllergy. 2016 ; 77 : 5.
 
3) 伊藤明子. ヘアカラー成分の陽性率 : PPDの貼布で酸化染毛剤のかぶれをスクリーニング. Visual Dermatol. 2018 ; 17 : 443-9.
 
4) Ito A, Nishioka K, Kanto H, et al. A multi-institutional joint study of contact dermatitis related to hair colouring and perming agents in Japan. Contact Dermatitis. 2017 ; 77 : 42-8.
PubMed
5) 鈴木丈雄, 伊藤明子, 会沢敦子. 酸化染毛剤による接触皮膚炎症候群. 臨皮. 2020 ; 42 : 30-3.
 
P.20 掲載の参考文献
1) 渡辺大輔. 帯状疱疹の診断と治療up-to-date. MB Derma. 2020 ; 297 : 30-8.
 
2) 渡辺大輔, 浅田秀夫, 山本千尋, 他. 水痘・帯状疱疹ウイルス抗原検出キットの基礎的, 臨床的性能評価. 新薬と臨. 2018 ; 67 : 23-34.
Medical*Online
3) Kimura H, Kido S, Ozaki T, et al. Comparison of quantitations of viral load in varicella and zoster. J Clin Microbiol. 2000 ; 38 : 2447-9.
PubMed
P.22 掲載の参考文献
1) 渡辺大輔, 浅田秀夫, 山本千尋, 他. 水痘・帯状疱疹ウイルス抗原検出キットの基礎的, 臨床的性能評価. 新薬と臨. 2018 ; 67 : 23-34.
Medical*Online
P.24 掲載の参考文献
1) Riggins RS, Ketcham AS. Effect of incisional biopsy on the development of experimental tumor metastasis. J Surg Res. 1965 ; 5 : 200-6.
PubMed
2) Rampen FH, van Houten WA, Jop WC. Incisional procedures and prognosis in malignant melanoma. Clin Exp Dermatol. 1980 ; 5 : 313-20.
PubMed
3) Pflugfelder A, Weide B, Eigentler TK, et al. Incisional biopsy and melanoma prognosis : fact and cotroversies. Clin Dermatol. 2010 ; 28 : 316-8.
 
4) Austin JR, Byers RM, Brown WD, et al. Influence of biopsy on the prognosis of cutaneous melanoma of the head and neck. Head Neck. 1996 ; 18 : 107-17.
PubMed
5) Shellenberger RA, Fayyaz F, Sako Z, et al. Impact of biopsy technique on clinically important outcomes for cutaneous melanoma : a systematic review and meta-analysis. Mayo Clin Proc Innov Qual Outcomes. 2020 ; 15 : 373-83.
 
P.26 掲載の参考文献
1) 秀道広, 森桶聡, 福永淳, 他. 蕁麻疹診療ガイドライン 2018. 日皮会誌. 2018 ; 128 : 2503-624.
 
2) 田中稔彦, 亀好良一, 秀 道広. 広島大学皮膚科外来での蕁麻疹の病型別患者数. アレルギー. 2006 ; 55 : 134-9.
Medical*Online
3) 中川優生, 千貫祐子, 新原寛之, 他. コリン性蕁麻疹と乏汗症. アレルギーの臨. 2017 ; 37 : 31-4.
 
P.29 掲載の参考文献
1) 塩野谷愛香, 肥田時征, 西坂尚大, 他. 肺扁平上皮癌に合併したBazex症候群の1例. 臨皮. 2020 ; 74 : 1101-6.
 
2) 出光俊郎. Carcinoid syndrome. In : 玉置邦彦, 総編集. 最新皮膚科学大系. 中山書店 ; 2004. p.62-3.
 
3) 鈴木友博, 田口良吉, 福田知雄, 他. 粘膜に限局した腫瘍随伴性天疱瘡. 皮膚臨. 2021 ; 63 : 19-22.
 
4) Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthitis Rheum. 2012 ; 64 : 513-22.
 
5) 段野喜一郎. In : 玉置邦彦, 編. 最新皮膚科学体系 3. 中山書店 ; 2002. p.173-83.
 
6) Wermers RA, Fatourechi V, Wynne AG, et al. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996 ; 75 : 53-63.
PubMed
7) Poszepczynska-Guigne E, Viguier M, Chosidow O, et al. Paraneoplastic acral vascular syndrome : epidemiologic features, clinical manifestations, and disease sequelae. J Am Acad Dermatol. 2002 ; 47 : 47-52.
PubMed
8) Schena D, Papagrigoraki A, Fringo A, et al. Eruptive disseminated porokeratosis associated with internal malignancies : a case report. Cutis. 2010 ; 85 : 156-9.
PubMed
P.33 掲載の参考文献
1) Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021 ; 7 : 86.
PubMed
2) Tamai K, Tachikawa R, Otsuka K, et al. Early pulmonary involvement of anti-CADM-140 autoantibody-positive rapidly progressive interstitial lung disease preceding typical cutaneous symptoms. Intern Med. 2014 ; 53 : 2515-9.
PubMed
3) Huang K, Vink O, Shojania K, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5) -positive dermatomyositis : a case－based review. Rheumatol Int. 2019 ; 39 : 1971-81.
 
4) Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody : study of 121 cases. Neurology. 2020 ; 95 : e70-8.
PubMed
5) Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease : a multicentre cohort of 497 patients. Rheumatology (Oxford). 2018 ; 57 : 1212-21.
PubMed
6) Li Y, Li Y, Wu J, et al. Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis. J Immunol Res. 2020 ; 2020 : 2024869.
 
P.39 掲載の参考文献
1) Mody E, Husni ME, Schur P, et al. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain : a dermatology : rheumatology clinic experience. Br J Dermatol. 2007 ; 157 : 1050-1.
PubMed
2) Maejima H, Katayama C, Taniguchi T, et al. Japanese version of the early psoriatic arthritis screening questionnaire (EARP). J Dermatol. 2016 ; 43 : 385-8.
 
3) Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015 ; 74 : 1045-50.
PubMed
4) Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis : development of new criteria from a large international study. Arthritis Rheum. 2006 ; 54 : 2665-73.
 
5) Takata T, Taniguchi Y, Ohnishi T, et al. 18FDG PET/CT is a powerful tool for detecting subclinical arthritis in patients with psoriatic arthritis and/or psoriasis vulgaris. J Dermatol Sci. 2011 ; 64 : 144-7.
PubMed
P.44 掲載の参考文献
1) 古川福実. 全身性エリテマトーデス (SLE) の診断. 診断基準には何が含まれる? Medical Note. 2015年12月1日. https://medicalnote.jp/contents/151117-000058-ABVDGL (2022年5月9日閲覧)
 
2) 宮地良樹. 蝶形紅斑. In : 宮地良樹, 編. 誤診されている皮膚疾患. メディカルレビュー社 ; 2013. p.84-7.
 
3) エリテマトーデス. In : 清水宏. あたらしい皮膚科学. 第3版. 中山書店 ; 2018. p.191-9.
 
4) 蝶形紅斑. In : 宮地良樹. 発疹のみかた. メディカルレビュー社 ; 2013. p.67-8.
 
P.48 掲載の参考文献
1) Bohme M, Svensson A, Kull I, et al. Hanifin's and Rajka's minor criteria for atopic dermatitis : Which do 2-year-olds exhibit? J Am Acad Dermatol. 2000 ; 43 : 785-92.
 
2) Brown SJ, Relton CL, Liao H, et al. Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema : further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. Br J Dermatol. 2009 ; 161 : 884-9.
 
3) Nomura T, Akiyama M, Sandilands A, et al. Prevalent and rare mutations in the gene encoding filaggrin in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Invest Dermatol. 2009 ; 129 : 1302-5.
PubMed
4) Nomura T, Akiyama M, Sandilands A, et al. Specific filaggrin mutations cause ichthyosis vulgaris and are significantly associated with atopic dermatitis in Japan. J Invest Dermatol. 2008 ; 128 : 1436-41.
PubMed
P.53 掲載の参考文献
1) 橋爪秀夫. 皮膚 (7) 多形紅斑. 日本臨牀. 2019 ; 77 (増刊号 4) : 41-6.
 
2) Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993 ; 129 : 92-6.
PubMed
3) Watanabe R, Watanabe H, Sotozono C, et al. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS) /toxic epidermal necrolysis (TEN). E J Dermatol. 2011 ; 21 : 889-94.
 
4) Hashizume H, Abe R, Azukizawa H, et al. Confusion in determination of two types of cutaneous adverse reactions to drugs, maculopapular eruption and erythema multiforme, among the experts : a proposal of standardized terminology. J Dermatol. 2020 ; 47 : 169-73.
PubMed
5) 塩原哲夫, 狩野葉子, 水川良子, 他. 日本皮膚科学会ガイドライン 重症多形滲出性紅斑 スティーヴンス・ジョンソン症候群・中毒性表皮壊死症診療ガイドライン. 日皮会誌. 2016 ; 126 : 1637-85.
 
6) Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010 ; 85 : 131-8.
 
7) Liu ZH, Shen H. Mycoplasma-induced toxic epidermal necrolysis with severe mucositis. J Allergy Clin Immunol Pract. 2019 ; 7 : 286-7.
PubMed
8) Burger E, Gou D, Vandergriff T, et al. Acute syndrome of pan-epidermolysis and thrombotic storm arising in a patient with systemic lupus erythematosus. JAAD Case Rep. 2018 ; 4 : 877-9.
 
9) Miyagawa F, Asada H. Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS). Int J Mol Sci. 2021 ; 22 : 2147.
PubMed
10) Nakamura-Nishimura Y, Miyagawa F, Miyashita K, et al. Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome. Br J Dermatol. 2018 ; 178 : 1430-2.
PubMed
P.56 掲載の参考文献
1) 仲弥, 宮川俊一, 服部尚子, 他. 足白癬・爪白癬の実態と潜在罹患率の大規模疫学調査 (Foot Check 2007). 日臨皮会誌. 2009 ; 26 : 27-36.
 
2) 楠俊雄, 楠万左子. 開業医における水虫患者の実態. 日皮会誌. 1995 ; 105 : 483.
 
3) 常深祐一郎. 爪白癬と鑑別が必要な爪の異常は? 皮膚臨. 2011 ; 53 : 1568-75.
 
4) 常深祐一郎. 足白癬を完治させる7の極意. 日本医事新報. 2020 ; 5002 : 18-26.
Medical*Online
5) Tsunemi Y, Takehara K, Oe M, et al. Diagnostic accuracy of tinea unguium based on clinical observation. J Dermatol. 2015 ; 42 : 221-2.
PubMed
6) Goto T, Nakagami G, Takehara K, et al. Examining the accuracy of visual diagnosis of tinea pedis and tinea unguium in aged care facilities. J Wound Care. 2017 ; 26 : 179-83.
 
7) 望月隆. 皮膚真菌症の検査法. 日皮会誌. 2009 ; 119 : 151-6.
 
8) 望月隆, 坪井良治, 五十棲健, 他. 日本皮膚科学会皮膚真菌症診療ガイドライン 2019. 日皮会誌. 2019 ; 129 : 2639-73.
 
9) 常深祐一郎, 穀澤恭一, 川島眞. 爪白癬診療における真菌検査の実態調査. 日臨皮会誌. 2016 ; 33 : 471-6.
 
P.60 掲載の参考文献
1) Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984 ; 76 : 377-84.
PubMed
2) 川名誠司, 陳科榮. 皮膚血管炎. 医学書院 ; 2013. p.267-73.
 
3) Watts RA, Carruthers DM, Scott DG. Isolated nail fold vasculitis in rheumatoid arthritis. Ann Rheum Dis. 1995 ; 54 : 927-9.
PubMed
P.67 掲載の参考文献
1) Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity : dependence on its finding and the type of drug eruption. Allergy. 2007 ; 62 : 1439-44.
 
2) Chung WH, Shih SR, Chang CF, et al. Clinicopathological analysis of Coxsackie A6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013 ; 208 : 1968-78.
 
3) Fruehauf J, Massone C, Muellegger RR. Bullous popular-purpuric gloves and socks syndrome in a 42-year-old female : molecular detection of parvoB19 DNA in lesional skin. J Am Acad Dermatol. 2009 ; 60 : 691-5.
 
4) Hayakawa J, Takakura H, Mizukawa Y, et al. COVID-19-related cutaneous manifestations associated with multiple drug sensitization as shown by lymphocyte transformation test. J Eur Acad Dermatol Venereol. 2020 ; 34 : e779-81.
 
5) Herman A, Matthews M, Mairlot M, et al. Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19. J Eur Acad Dermatol Venereol. 2020 ; 34 : e768-e770.
 
6) Patel KN, Hussain M, Khalil A, et al. Infectious mononucleosis presenting with loss of taste and smell during the SARS-COV-2 pandemic? Eur J Case Rep Intern Med. 2020 ; 7 : 002048.
PubMed
P.73 掲載の参考文献
1) 渡辺大輔, 五十嵐敦之, 江川清文, 他. 尋常性疣贅診療ガイドライン 2019 第1版. 日皮会誌. 2019 ; 129 : 1265-92.
 
2) Hung CY, Sun PL, Chiang SJ, et al. In vitro differential diagnosis of clavus and verruca by a predictive model generated from electrical impedance. PLoS One. 2014 ; 9 : e93647.
PubMed

病態をめぐるControversy

P.77 掲載の参考文献
1) 足立厚子, 堀川達弥. 全身型金属アレルギー 食事制限の有効性について. 臨皮. 1992 ; 46 : 883-9.
 
2) 足立厚子. 金属接触アレルギーと全身型金属アレルギー. J Environ Dermatol Cutan Allergol. 2009 ; 3 : 413-22.
Medical*Online
3) Veien NK, Hattel T, Justesen O, et al. Oral challenge with metal salts. (I). Vesicular patch-test-negative hand eczema. Contact Dermatitis. 1983 ; 9 : 402-6.
PubMed
4) Adachi A, Horikawa T. The significance, problem and method of oral provocation test in metal allergy. Environ Dermatol. 1999 ; 6 : 74-82.
 
5) Veien NK, Hattel T, Laurberg G. Low nickel diet : an open, prospective trial. J Am Acad Dermatol. 1993 ; 29 : 1002-7.
 
6) Gawkrodger DJ, Cook SW, Fell GS, et al. Nickel dermatitis. The reaction to oral nickel challenge. Br J Dermatol. 1986 ; 115 : 33-8.
PubMed
7) Andreassi M, Gioacchino M, Sabbioni E, et al. Serum and urine nickel in nickel-sensitized women : effects of oral challenge with the metal. Contact Dermatitis. 1998 ; 38 : 5-8.
PubMed
8) Nierlsen GD, Jepsen LV, Jorgensen PJ, et al. Nickel-sensitive patients with vesicular hand eczema, oral challenge with a diet naturally high in nickel. Br J Dermatol. 1990 ; 122 : 299-308.
 
9) Medeiros LM, Fransway AF, Taylor JS, et al. Complementary and alternative remedies : an additional source of potential systemic nickel exposure. Contact Dermatitis. 2008 ; 58 : 97-100.
PubMed
10) 鷲尾文郎, 足立厚子, 近藤真史, 他. ビタミンB12製剤による薬疹, 臨床的特徴およびコバルトアレルギーの関与について. 皮病診療. 1994 ; 16 : 597-600.
 
P.80 掲載の参考文献
1) Strrs FJ. Acute and recurrent vesicular hand dermatitis not pompholysx or dyshidorosis. Arch Dermatol. 2007 ; 143 : 1578-80.
PubMed
2) Lee WJ, Lee DW, Kim CH, et al. Pompholyx with bile-coloured vesicles in a patient with jaundice : are sweat ducts involved in the development of pompholyx? J Eur Acad Dermatol Venereol. 2010 ; 24 : 235-6.
 
3) Fisher AA. Contact Dermatitis. 3rd ed. Philadelphia : Lea & Febiger ; 1986. p.119-30.
 
4) Nishizawa A. Dyshidrotic eczema and its relationship to metal allergy. Curr Probl Dermatol. 2016 ; 51 : 80-5.
PubMed
5) 西澤綾. 手湿疹の治療. Derma. 2016 ; 248 : 34-40.
 
P.83 掲載の参考文献
1) Nakayama H, Nogi N, Kasahara N, et al. Allergen control. An indispensable treatment for allergic contact dermatitis. Dermatol Clin. 1990 ; 8 : 197-204.
PubMed
2) Kosugi M, Ishihara K, Okuda K. Implication of responses to bacterial heat shock proteins, chronic microbial infections, and dental metal allergy in patients with pustulosis palmaris et plantaris. Bull Tokyo Dent Coll. 2003 ; 44 : 149-58.
PubMed
3) Dantzing P. The role of mercury in pustulosis palmaris et plantaris. J Occup Environ Med. 2003 ; 45 : 468-9.
 
4) Yanagi T, Shimizu T, Abe R, et al. Zinc dental fillings and palmoplantar pustulosis. Lancet. 2005 ; 366 : 1050.
PubMed
5) Song H, Yin W, Ma Q. Allergic palmoplantar pustulosis caused by cobalt in cast dental crowns : a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 ; 111 : e8-10.
PubMed
6) 伊藤明子. これだけは知っておきたい接触皮膚炎の基礎知識 金属アレルギーとパッチテスト-歯科との連携の重要性. 医のあゆみ. 2012 ; 240 : 601-7.
 
7) 松村康子, 内田敬久, 藤村奈緒, 他. 金属亜鉛が原因と考えられる掌蹠膿疱症の一例. アレルギーの臨. 2013 ; 33 : 740-4.
 
8) Nakamura K, Imakado S, Takizawa M, et al. Exacerbation of pustulosis palmaris et plantaris after topical application of metals accompanied by elevated levels of leukotriene B4 in pustules. J Am Acad Dermatol. 2000 ; 42 : 1021-5.
PubMed
9) 渡邉友也, 内田敬久, 広田理映, 他. ロイコトリエン拮抗薬内服で改善したと思われる掌蹠膿疱症の1例. 皮膚臨床. 2014 ; 12 : 2108-11.
 
10) Masui Y, Ito A, Akiba Y, et al. Dental metal allergy is not the main cause of palmoplantarpustulosis. J Eur Acad Dermatol Venereol. 2019 ; 33 : 180-1.
 
P.87 掲載の参考文献
1) Yonezawa K, Haruna M, Matsuzaki M, et al. Effects of moisturizing skincare on skin barrier function and the prevention of skin problems in 3-month-old infants : a randomized controlled trial. J Dermatol. 2018 ; 45 : 24-30.
PubMed
2) Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014 ; 134 : 824-30.e6.
 
3) Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014 ; 134 : 818-23.
PubMed
4) Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema : the BEEP randomised controlled trial. Lancet. 2020 ; 395 : 962-72.
PubMed
5) Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL) : a factorial, multicentre, cluster-randomised trial. Lancet. 2020 ; 395 : 951-61.
PubMed
6) Kelleher MM, Cro S, Van Vogt E, et al. Skincare interventions in infants for preventing eczema and food allergy : a cochrane systematic review and individual participant data meta-analysis. Clin Exp Allergy. 2021 ; 51 : 402-18.
PubMed
7) Boralevi F, Saint Aroman M, Delarue A, et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014 ; 28 : 1456-62.
PubMed
8) Dissanayake E, Tani Y, Nagai K, et al. Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants : a 2×2 factorial, randomized, non-treatment controlled trial. Int Arch Allergy Immunol. 2019 ; 180 : 202-11.
 
9) Landheer J, de Bruin-Weller M, Boonacker C, et al. Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity. J Am Acad Dermatol. 2014 ; 71 : 1160-6.
PubMed
10) Danso MO, van Drongelen V, Mulder A, et al. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014 ; 134 : 1941-50.
 
11) Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization : the PEBBLES pilot study. Br J Dermatol. 2018 ; 178 : e19-21.
PubMed
12) Duan Y, Ma L, Galzote C, et al. A randomized pilot clinical assessment of three skincare regimens on skin conditions in infants. Clin Cosmet Investig Dermatol. 2019 ; 12 : 895-909.
PubMed
13) Garcia Bartels N, Mleczko A, Schink T, et al. Influence of bathing or washing on skin barrier function in newborns during the first four weeks of life. Skin Pharmacol Physiol. 2009 ; 22 : 248-57.
PubMed
P.91 掲載の参考文献
1) 高橋歩, 今野哲, 伊佐田朗, 他. 気管支喘息及び鼻炎における血清lIgE値及び末梢血好酸球数の検討. アレルギー. 2010 ; 59 : 536-44.
 
2) 高松由佳, 竹原和彦, 高村利治, 他. 医学部学生における特異IgE抗体の検討. 日皮会誌. 1998 ; 108 : 953-8.
 
3) 大阪AD研究会. アトピー性皮膚炎の重症度とIgE, LDH, 好酸球との相関と抗アレルギー薬による治療効果の影響. 皮膚. 2000 ; 42 : 276-84.
 
4) 古江増隆. アトピー性皮膚炎オーバービュー-病態はどこまでわかっているか? In : 古江増隆, 編. Dermatology Practice アトピー性皮膚炎. 文光堂 ; 1999. p.4-5.
 
5) 葉山惟大. 慢性特発性蕁麻疹の診断・治療の最新情報. 日大医誌. 2020 ; 79 : 93-7.
 
6) Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005 ; 53 : 338-40.
PubMed
7) Snast I, Reiter O, Hodak E, et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018 ; 19 : 145-65.
 
8) Yamamoto T, Kaneko S, Hide M, et al. Increase in serum IgE levels following injection of syngeneic keratinocyte extracts in BALB/c mice. Arch Dermatol Res. 2002 ; 294 : 117-23.
PubMed
9) 奥平博一, 工藤宏一郎, 宮本昭正. IgE抗体産生の細胞機構. Jpn J Clin Immonol. 1983 ; 6 : 359-64.
 
10) 高田英俊, 峯岸克行. 高IgE症候群の最近の話題. Jpn J Clin Immonol. 2010 ; 33 : 15-9.
 
11) Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis : a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007 ; 120 : 164-70.
PubMed
12) Yagi R, Nagai H, Iigo Y, et al. Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice. J Immunol. 2002 ; 168 : 2020-7.
PubMed
13) 戸倉新樹. 内因性アトピー性皮膚炎. 皮病診療. 2020 ; 42 : 856-60.
 
14) Kaneko S, Furutani K, Koro O, et al. Transient shift toward T helper 1 cytokine production by peripheral blood mononuclear cells following successful treatment of patients with atopic dermatitis. Allergol Int. 2003 ; 52 : 21-9.
 
P.94 掲載の参考文献
1) 秀道広, 森桶聡, 福永淳, 他. 蕁麻疹診療ガイドライン 2018. 日皮会誌. 2018 ; 128 : 2503-624.
 
2) Taskapan O, Kutlu A, Karabudak O. Evaluation of autologous serum skin test results in patients with chronic idiopathic urticaria, allergic/non-allergic asthma or rhinitis and healthy people. Clin Exp Dermatol. 2008 ; 33 : 754-8.
PubMed
3) Altrichter S, Peter HJ, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase-a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011 ; 6 : e14794.
PubMed
4) MacGlashan D. Auto-antibodies to IgE and FceRI and the natural variability of SYK expression in basophils. J Allergy Clin Immunol. 2018 ; 143 : 1100-7.e11.
 
5) Saini SS, Paterniti M, Vasagar K, et al. Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization : relationship to expression of Syk and SHIP-2. Clin Immunol. 2009 ; 132 : 342-8.
PubMed
P.97 掲載の参考文献
1) Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project : expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018 ; 32 : 1059-65.
PubMed
2) 長島正治. 痒疹丘疹の特徴. 皮膚臨床. 1995 ; 37 : 1211.
 
3) Ugajin T, Yokozeki H. Efficacy of anti-immunoglobulin E therapy in patients with prurigo, a pilot study. J Cutan Immunol Allergy. 2019 ; 2 : 75-81.
 
4) Kossard S, Hamann I, Wilkinson B. Defining urticarial dermatitis : a subset of dermal hypersensitivity reaction pattern. Arch Dermatol. 2006 ; 142 : 29-34.
PubMed
P.101 掲載の参考文献
1) Amon U, Wolff HH. Healing of chronic atopic dermatitis lesions in skin areas of paraplegia after trauma. J Dermatol. 1994 ; 21 : 982-3.
PubMed
2) 足立晃正, 細田里美, 小宮根真弓, 他. 脊髄損傷患者の感覚残存部位のみに皮疹がみられた慢性多形痒疹の1例. 日皮会誌. 2014 ; 124 : 785.
 
3) Almustafa ZZ, Weller K, Autenrieth J, et al. Dupilumab in treatment of chronic prurigo : a case series and literature review. Acta Derm Venereol. 2019 ; 99 : 905-6.
PubMed
4) Stander S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020 ; 382 : 706-16.
PubMed
5) Ugajin T, Inazawa M, Inui K, et al. A case of chronic prurigo successfully treated with omalizumab. Eur J Dermatol. 2018 ; 28 : 691-2.
PubMed
6) Inui K, Ugajin T, Namiki T, et al. Chronic prurigo : a retrospective study of 168 cases. J Dermatol. 2020 ; 47 : 283-9.
 
7) Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017 ; 171 : 217-28 e13.
 
8) Katayama C, Hayashida Y, Sugiyama S, et al. Prurigo nodularis as a sweat gland/duct-related disorder : resolution associated with restoration of sweating disturbance. Arch Dermatol Res. 2019 ; 311 : 555-62.
PubMed
9) Ko KC, Tominaga M, Kamata Y, et al. Possible antipruritic mechanism of cyclosporine A in atopic dermatitis. Acta Derm Venereol. 2016 ; 96 : 624-9.
PubMed
10) Bernard JJ, Cowing-Zitron C, Nakatsuji T, et al. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat Med. 2012 ; 18 : 1286-90.
PubMed
11) Szollosi AG, McDonald I, Szabo IL, et al. TLR3 in chronic human itch : a keratinocyte-associated mechanism of peripheral itch sensitization. J Invest Dermatol. 2019 ; 139 : 2393-6.e6.
 
12) Liu T, Berta T, Xu ZZ, et al. TLR3 deficiency impairs spinal cord synaptic transmission, central sensitization, and pruritus in mice. J Clin Invest. 2012 ; 122 : 2195-207.
PubMed
13) 片桐一元. 多形慢性痒疹治療アルゴリズム. 臨皮. 2014 ; 68 : 94-8.
 
P.105 掲載の参考文献
1) Hartmann K, Henz BM. Mastocytosis : recent advances in defining the disease. Br J Dermatol. 2001 ; 144 : 682-95.
PubMed
2) Meni C, Bruneau J, Bodemer C, et al. Paediatric mastocytosis : a systematic review of 1747 cases. Br J Dermatol. 2015 ; 172 : 642-51.
PubMed
3) 金澤信雄. 蕁麻疹と鑑別を要する遺伝性疾患. 日小児アレルギー会誌. 2020 ; 34 : 253-63.
 
4) Valent P, Akin C, Hartmann K, et al. Advances in the classification and treatment of mastocytosis : current status and outlook toward the future. Cancer Res. 2017 ; 77 : 1261-70.
PubMed
5) Murphy M, Walsh D, Drumm B, et al. Bullous mastocytosis : a fatal outcome. Pediatr Dermatol. 1999 ; 16 : 452-5.
PubMed
6) 竹澤香織, 神戸直智. 肥満細胞腫 (肥満細胞症). 小児診療. 2019 ; 82 : 1426-30.
Medical*Online
7) 本多浩, 大橋威信, 柳堀浩克, 他. 過去25年間に当科で経験した, 肥満細胞症患者30例の臨床的解析. 日皮免疫アレルギー会誌. 2020 ; 3 : 413-9.
 
P.113 掲載の参考文献
1) 泉美貴. みき先生の皮膚病理診断ABC (1) 表皮系病変. 第2版. 学研メディカル秀潤社, 2021. p.58-87.
 
2) Hafner C, Hartmann A, van Oers JMM, et al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Modern Pathol. 2007 ; 20 : 895-903.
 
3) Hafner C, Stoehr R, van Oers JMM, et al. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo. Br J Dermatol. 2009 ; 160 : 546-51.
 
4) Sloan JB, Jaworsky C. Clinical misdiagnosis of squamous cell carcinoma in situ as seborrheic keratosis. A prospective study. J Dermatol Surg Oncol. 1993 ; 19 : 413-6.
 
5) Rajabi P, Adibi N, Nematollahi P, et al. Bowenoid transformation in seborrheic keratosis : a retrospective analysis of 429 patients. J Res Med Sci. 2012 ; 17 : 217-21.
PubMed
P.116 掲載の参考文献
1) Minagawa A, Omodaka T, Okuyama R. Melanomas and mechanical stress points on the plantar surface of the foot. N Engl J Med. 2016 ; 374 : 2404-6.
PubMed
2) Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015 ; 373 : 1926-36.
PubMed
3) Tsao H, Bevona C, Goggins W, et al. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma : a population-based estimate. Arch Dermatol. 2003 ; 139 : 282-8.
PubMed
4) Ferrara G, Argenyi Z, Argenziano G, et al. The influence of clinical information in the histopathologic diagnosis of melanocytic skin neoplasms. PLoS One. 2009 ; 4 : e5375.
PubMed
P.119 掲載の参考文献
1) Zouboulis CC, Boschnakow A. Chronological ageing and photoageing of the human sebaceous gland. Clin Exp Dermatol. 2001 ; 26 : 600-7.
PubMed
2) Pochi PE, Strauss JS, Downing DT. Age-related changes in sebaceous gland activity. J Invest Dermatol. 1979 ; 73 : 108-11.
PubMed
3) Fenske NA, Lober CW. Structural and functional changes of normal aging skin. J Am Acad Dermatol. 1986 ; 15 : 571-85.
PubMed
4) Makrantonaki E, Adjaye J, Herwig R, et al. Age-specific hormonal decline is accompanied by transcriptional changes in human sebocytes in vitro. Aging Cell. 2006 ; 5 : 331-44.
PubMed
5) Iacobelli J, Harvey NT, Wood BA. Sebaceous lesions of the skin. Pathology. 2017 ; 49 : 688-97.
PubMed
6) Plewig G, Kligman AM. Proliferative activity of the sebaceous glands of the aged. J Invest Dermatol. 1978 ; 70 : 314-17.
PubMed
7) Akamatsu H, Zouboulis CC, Orfanos CE. Control of human sebocyte proliferation in vitro by testosterone and 5-α-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol. 1992 ; 99 : 509-11.
 
8) Lesnik RH, Kligman LH, Kligman AM. Agents that cause enlargement of sebaceous glands in hailess mice. II. Ultraviolet radiation. Arch Dermatol Res. 1992 ; 284 : 106-8.
PubMed
9) Harwood CA, Swale VJ, Bataille VA, et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol. 2001 ; 116 : 246-53.
PubMed
10) Leyden J. What is photoaged skin? Eur J Dermatol. 2001 ; 11 : 165-7.
PubMed
11) Lauri A, Pompilio G, Capogrossi MC. The mitochondrial genome in aging and senescence. Ageing Res Rev. 2014 ; 18 : 1-15.
PubMed
12) Shenk JL, Fisher CJ, Chen SY, et al. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem. 2001 ; 276 : 38472-9.
PubMed
13) Alimirah F, Panchanathan R, Chen J, et al. Expression of androgen receptor is negatively regulated by p53. Neoplasia. 2007 ; 9 : 1152-9.
PubMed
14) Nantermet PV, Xu J, Yu Y, et al. Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J Biol Chem. 2004 ; 279 : 1310-22.
 
15) Rokhlin OW, Taghiyev AF, Guseva NV, et al. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene. 2005 ; 24 : 6773-84.
PubMed
16) Cottle DL, Kretzschmar K, Schweiger PJ, et al. c-MYC-induced sebaceous gland differentiation is controlled by an androgen receptor/p53 axis. Cell Rep. 2013 ; 3 : 427-41.
PubMed
17) Campbell C, Quinn AG, Angus B, et al. Wavelength specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res. 1993 ; 53 : 2697-9.
PubMed
18) Hall PA, McKee PH, Menage HD, et al. High levels of p53 protein in UV-irradiated normal human skin. Oncogene. 1993 ; 8 : 203-7.
PubMed
19) Takahashi S, Pearse AD, Marks R. The acute effects of ultraviolet-B radiation on c-myc and c-Ha ras expression in normal human epidermis. J Dermatol Sci. 1993 ; 6 : 165-71.
 
20) Han G, Li AG, Liang YY, et al. Smad7-induced beta-catenin degradation alters epidermal appendage development. Dev Cell. 2006 ; 11 : 301-12.
PubMed
21) Foley J, Longely BJ, Wysolmerski JJ, et al. PTHrP regulates epidermal differentiation in adult mice. J Invest Dermatol. 1998 ; 111 : 1122-8.
PubMed
22) Groesser L, Singer S, Peterhof E, et al. KRAS, HRAS and EGFR mutations in sporadic sebaceous gland hyperplasia. Acta Derm Venereol. 2016 ; 96 : 737-41.
PubMed
23) de Berker DA, Taylor AE, Quinn AG, et al. Sebaceous hyperplasia in organ transplant recipients : shared aspects of hyperplastic and dysplastic processes? J Am Acad Dermatol. 1996 ; 35 : 696-9.
PubMed
P.123 掲載の参考文献
1) Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea : a preliminary report. J Am Acad Dermatol. 2001 ; 44 : 995-8.
PubMed
2) Bamford JTM, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004 ; 50 : 107-8.
 
3) Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea : an 8-week split-face clinical trial. Br J Dermatol. 2008 ; 158 : 1069-76.
PubMed
4) Lubbe J, Stucky L, Saurat JH. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology. 2003 ; 207 : 204-5.
PubMed
5) Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004 ; 140 : 457-60.
PubMed
6) Fujiwara S, Okubo Y, Irisawa R, et al. Rosaceiform dermatitis associated with topical tacrolimus treatment. J Am Acad Dermatol. 2010 ; 62 : 1050-2.
PubMed
7) Teraki Y, Hitomi K, Sato Y, et al. Tacrolimus-induced rosacea-like dermatitis : a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology. 2012 ; 224 : 309-14.
PubMed
8) Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011 ; 131 : 688-97.
PubMed
9) Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007 ; 13 : 975-80.
PubMed
10) Shibata M, Katsuyama M, Onodera T, et al. Glucocorticoids enhance toll-like receptor 2 expression in human keratinocytes stimulated with propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009 ; 129 : 375-82.
PubMed
11) Buchau AS, Schauber J, Hultsch T, et al. Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol. 2008 ; 128 : 2646-54.
PubMed
P.126 掲載の参考文献
1) Smith RN, Mann NJ, Braue A, et al. A low-glycemic-load diet improves symptoms in acne vulgaris patients : a randomized controlled trial. Am J Clin Nutr. 2007 ; 86 : 107-15.
PubMed
2) Kwon H, Yoon J, Hong J, et al. Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients : a randomized, controlled trial. Acta Derm Venereol. 2012 ; 92 : 241-6.
PubMed
3) Cao H, Yang G, Wang Y, et al. Complementary therapies for acne vulgaris. Cochrane Database Syst Rev. 2015 ; Jan 19 ; 1 : CD009436.
 
4) Aghasi M, Golzarand M, Shab-Bidar S, et al. Dairy intake and acne development : A meta-analysis of observational studies. Clin Nutr. 2019 ; 38 : 1067-75.
PubMed
5) Melnik BC, Zouboulis CC. Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol. 2013 ; 22 : 311-5.
PubMed
6) Silverberg N. Whey protein precipitating moderate to severe acne flares in 5 teenaged athletes. Cutis. 2012 ; 90 : 70-2.
PubMed
7) Simonart T. Acne and whey protein supplementation among body-builders. Dermatology. 2012 ; 225 : 256-8.
 
8) Fulton JE Jr, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA. 1969 ; 210 : 2071-4.
PubMed
9) Wolkenstein P, Machovcova A, Szepietowski JC, et al. Acne prevalence and associations with lifestyle : a cross-sectional online survey of adolescents/young adults in 7 European countries. J Eur Acad Dermatol Venereol. 2018 ; 32 : 298-306.
PubMed
10) Caperton C, Block S, Viera M, et al. Double-blind, placebo-controlled study assessing the effect of chocolate consumption in subjects with a history of acne vulgari. J Clin Aesthet Dermatol. 2014 ; 7 : 19-23.
 
11) Delost GR, Delost ME, Lloyd J. The impact of chocolate consumption on acne vulgaris in college students : a randomized crossover study. J Am Acad Dermatol. 2016 ; 75 : 220-2.
 
12) Vongraviopap S, Asawanonda P. Dark chocolate exacerbates acne. Int J Dermatol. 2016 ; 55 : 587-91.
PubMed
13) Block SG, Valins WE, Caperton CV, et al. Exacerbation of facial acne vulgaris after consuming pure chocolate. J Am Acad Dermatol. 2011 ; 65 : e114-5.
PubMed
P.129 掲載の参考文献
1) Hayashi N, Akamatsu H, Iwatsuki K, et al. Japanese Dermatological Association Guidelines : Guidelines for the treatment of acne vulgaris 2017. J Dermatol. 2018 ; 45 : 898-935.
PubMed
2) Nakase K, Nakaminami H, Takenaka Y, et al. Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in Japan. J Med Microbiol. 2014 ; 63 : 721-8.
 
3) Nakase K, Hayashi N, Akiyama Y, et al. Antimicrobial susceptibility and phylogenetic analysis of Propionibacterium acnes isolated from acne patients in Japan between 2013 and 2015. J Dermatol. 2017 ; 44 : 1248-54.
PubMed
4) Nakase K, Aoki S, Sei S, et al. Characterization of acne patients carrying clindamycin-resistant Cutibacterium acnes : a Japanese multicenter study. J Dermatol. 2020 ; 47 : 863-9.
PubMed
5) Aoki S, Nakase K, Hayashi N, et al. Transconjugation of erm (X) conferring high-level resistance of clindamycin for Cutibacterium acnes. J Med Microbiol. 2019 ; 68 : 26-30.
PubMed
6) Aoki S, Nakase K, Nakaminami H, et al. Transferable multidrug-resistance plasmid carrying a novel macrolide-clindamycin resistance gene, erm (50), in Cutibacterium acnes. Antimicrob Agents Chemother. 2020 ; 64 : e01810-19.
PubMed
7) Nakase K, Nakaminami H, Takenaka Y, et al. Propionibacterium acnes is developing gradual increase in resistance to oral tetracyclines. J Med Microbiol. 2017 ; 66 : 8-12.
PubMed
P.132 掲載の参考文献
1) Kazandjieva JS, Tsankov NK. Drug-induced acne. In : Zouboulis CC, et al, editors. Pathogenesis and treatment of acne and rosacea. New York : Springer ; 2014. p.251-7.
 
2) Farris PK, Murina A. Malassezia folliculitis. In : Zeichner JA, editor. Acneiform eruptions in dermatology : a differential diagnosis. New York : Springer ; 2014. p.59-65.
 
3) Malasszia (Pityrosporum) folliculitis. In : Plewig G, et al, editors. 4th ed. Plewig and Kligman's acne and rosacea. New York : Springer ; 2019 p.317-8.
 
4) Yu HJ, Lee SK, Son SJ, et al. Steroid acne vs. Pityrosporum folliculitis : the incidence of Pityrosporum ovale and the effect of antifungal drugs in steroid acne. Int J Dermatol. 1998 ; 37 : 772-9.
PubMed
P.136 掲載の参考文献
1) Hayama K, Fujita H, Hashimoto T, et al ; Japanese HS Research Group. Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries. J Dermatol. 2020 ; 47 : 743-8.
 
2) Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020 ; 6 : 18.
PubMed
3) 葉山惟大, 井上里佳, 大槻マミ太郎, 他. 化膿性汗腺炎診療の手引き 2020. 日皮会誌. 2021 ; 131 : 1-28.
 
4) Zouboulis CC, Desai N, Emtetam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015 ; 29 : 619-44.
 
5) Williams SC, Frew JW, Krueger JG. A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa. Exp Dermatol. 2021 ; 30 : 1388-97.
PubMed
6) Naik HB, Jo JH, Paul M, et al. Skin microbiota perturbations are distinct and disease severity-dependent in hidradenitis suppurativa. J Invest Dermatol. 2020 ; 140 : 922-5.e3.
 
7) 葉山惟大. 化膿性汗腺炎の新しい概念と治療. 臨皮. 2018 ; 72 : 132-7.
 
8) Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis supprativa/acne inversa, based on the European guidelines for hidradenitis supprativa. Rev Endocr Metad Disord. 2016 ; 17 : 343-51.
 
P.140 掲載の参考文献
1) 伊藤明, 高橋晴人, 永野ひろ美, 他. 皮膚科医からみた「敏感肌」の実態とその認識. 臨皮. 2000 ; 54 : 109-12.
 
2) 江藤隆史. 皮膚科医からみた敏感肌. 香粧会誌. 2005 ; 29 : 125-9.
 
3) 沼上克子, 田上八朗. 敏感肌. 臨皮. 2000 ; 54 : 188-9.
 
4) Berardesca E, Maibach HI. Sensitive and ethnic skin. A need for special skin-care agents? Dermatol Clin. 1991 ; 9 : 89-92.
PubMed
5) Kamide R, Misery L, Perez-Cullell N, et al. Sensitive skin evaluation in the Japanese population. J Dermatol. 2013 ; 40 : 177-81.
PubMed
6) 石田耕一. 敏感肌とは何か? Bella Pelle. 2016 ; 1 : 90-3.
Medical*Online
7) Richters R, Falcone D, Uzunbajakava N, et al. What is sensitive skin? A systematic literature review of objective measurements. Skin Pharmacol Physiol. 2015 ; 28 : 75-83.
PubMed
8) 小川朋康, 柳沢真由美, 桑原裕史. 敏感肌におけるスティンギングテストと感受性に関する考察. Fragrance J. 2002 ; 30 : 37-42.
 
9) Frosch PJ, Kligman AM. A method for appraising the stinging capacity of topically applied substances. J Soc Cosmet Chem. 1977 ; 28 : 197-209.
 
10) Kobayashi M, Ito K, Sugita T, et al. Physiological and microbiological verification of the benefit of hair washing in patients with skin conditions of the scalp. J Cosmet Dermatol. 2016 ; 15 : e1-8.
PubMed
11) 横田朋宏. 皮膚生理パラメーター解析による敏感肌タイプ分類. 香粧会誌. 2005 ; 29 : 44-9.
 
12) 高森建二. かゆみと敏感肌. 香粧会誌. 2005 ; 29 : 130-3.
 
13) Misery L, Loser K, Stander S. Sensitive skin. J Eur Acad Dermatol Venereol. 2016 ; 30 (Suppl 1) : 2-8.
 
14) 針谷毅. 敏感肌の特性. 香粧会誌. 2005 ; 29 : 35-43.
 
15) 池野宏. 臨床医からみた敏感肌とその治療. Fragrance J. 2002 ; 30 : 41-7.
 
16) Muizzuddin N, Marenus KD, Maes DH. Factors defining sensitive skin and its treatment. Am J Contact Dermat. 1998 ; 9 : 170-5.
PubMed

治療をめぐるControversy

P.144 掲載の参考文献
1) Hajar T, Lesham YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015 ; 72 : 541-9.
 
2) 日本皮膚科学会, 日本アレルギー学会, アトピー性皮膚炎診療ガイドライン作成委員会. アトピー性皮膚炎診療ガイドライン 2021. 日皮会誌. 2021 ; 131 : 2691-777.
 
3) Schmitt J, von Kobyletzki L, Svensson A, et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema : systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011 ; 164 : 415-28.
PubMed
4) Caproni M, Torchia D, Antiga E, et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis : an immunohistochemical study. Br J Dermatol. 2007 ; 156 : 312-9.
PubMed
5) Simon D, Vassina E, Yousefi S, et al. Reduced dermal infiltration of cytokine expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol. 2004 ; 114 : 887-95.
PubMed
P.147 掲載の参考文献
1) de Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable : a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018 ; 178 : 1083-101.
 
2) Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016 ; 375 : 2335-48.
PubMed
3) Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS) : a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 ; 389 : 2287-303.
 
P.150 掲載の参考文献
1) 医薬品医療機器総合機構ウェブサイト. 最適使用推進ガイドライン デュピルマブ. 平成30年4月. https://www.pmda.go.jp/files/000237674.pdf (2022年5月閲覧)
 
2) 川島眞, 瀧川雅浩, 中川秀己, 他. アトピー性皮膚炎治療ガイドライン. 日皮会誌. 2000 ; 110 : 1099-104.
 
3) Reed B, Blaiss MS. The burden of atopic dermatitis. Allergy Asthma Proc. 2018 ; 39 : 406-10.
PubMed
4) Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol. 2014 ; 133 : 1615-25.e1.
 
5) Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012 ; 24 : 253-60.
PubMed
6) 片岡葉子. アトピー性皮膚炎のタイト & セーフコントロール. Derma. 2018 ; 265 : 33-9.
 
7) Guttman YE, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 ; 143 : 155-72.
 
8) Bangert C, Rindler K, Krausgruber T, et al. Persistence of mature dendritic cells, TH 2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade. Sci Immunol. 2021 ; 6 : eabe2749.
 
9) Worm M, Simpson EL, Thaci D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis : a randomized clinical trial. JAMA Dermatol. 2020 ; 156 : 131-43.
PubMed
10) 平田信太郎, 田中良哉. バイオシミラー・バイオフリーについて : 治療費軽減対策. 内科. 2016 ; 117 : 1195-201.
 
11) Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2020 ; 79 : 685-99.
PubMed
12) Shi L, Lian N, Liu L, et al. Tapering and discontinuation of systemic medications in psoriasis patients with low disease activity. Dermatol Ther. 2020 ; 33 : e13599.
PubMed
P.152 掲載の参考文献
1) Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments : a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016 ; 387 : 40-52.
PubMed
2) Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016 ; 375 : 2335-48.
PubMed
3) Katoh N, Kataoka Y, Saeki H, et al. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis : a subanalysis of three clinical trials. Br J Dermatol. 2020 ; 183 : 39-51.
PubMed
4) Worm M, Simpson EL, Thaci D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis : a randomized clinical trial. JAMA Dermatol. 2020 ; 156 : 131-43.
PubMed
5) Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS) : a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 ; 389 : 2287-303.
 
6) de Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable : a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018 ; 178 : 1083-101.
 
7) Deleuran M, Thaci D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020 ; 82 : 377-88.
 
8) Beck LA, Thaci D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020 ; 21 : 567-77.
 
9) Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab : a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018 ; 78 : 62-9.e1.
 
10) Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis : a comprehensive pooled analysis. Am J Clin Dermatol. 2019 ; 20 : 443-56.
PubMed
P.155 掲載の参考文献
1) Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis : a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020 ; 82 : 823-31.
 
2) Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis : a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018 ; 178 : 424-32.
PubMed
P.157 掲載の参考文献
1) 上野賢一, 大塚藤男. 皮膚科学 第8版. 金芳堂 ; 2006. p.664.
 
2) 加藤則人, 大矢幸弘, 池田政憲, 他. アトピー性皮膚炎診療ガイドライン 2018. 日皮会誌. 2018 ; 128 : 2431-502.
 
3) 渡辺大輔, 川島眞, 本田まりこ, 他. カポジ水痘様発疹症の診断・治療指針の検討. 臨医薬. 2016 : 32 ; 73-80.
Medical*Online
4) Wollenberg A, Zoch C, Wetzel S, et al. Predisposing factors and clinical features of eczema herpeticum : a retrospective analysis of 100 cases. J Am Acad Dermatol. 2003 ; 49 : 198-205.
 
P.160 掲載の参考文献
1) 玉置邦彦, 佐伯秀久, 門野岳史, 他. アトピー性皮膚炎の病勢指標としての血清TARC/CCL17値についての臨床的検討. 日皮会誌. 2006 ; 116 : 27-39.
 
2) Bieber T. Atopic dermatitis. Ann Dermatol. 2010 ; 22 : 125-37.
PubMed
3) Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis : serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001 ; 107 : 535-41.
PubMed
4) 片岡葉子. 新しい診断・検査法- (1) TARCの活用. 皮膚臨床. 2019 ; 61 ; 813-8.
 
5) 佐藤美聡, 布袋祐子. 当院におけるアトピー性皮膚炎に対するデュピルマブの使用経験. 日皮会誌. 2019 ; 129 ; 2755-62.
 
P.162 掲載の参考文献
1) Wakelin S. Seborrheic dermatitis. In : Griffiths C, et al, editors. Rook's Textbook of Dermatology. 9th ed. vol 2. part 4 : chapter 40. Singapore ; John Wiley & Sons ; 2016. p.1-6.
 
2) 清佳浩, 中林淳浩, 森下宣明, 他. 乳児脂漏性皮膚炎-特に常在菌のうち癜風菌の変動について-. 日小皮会誌. 2000 ; 19 : 101-4.
 
3) 清佳浩, 二宮純也, 浜口太造, 他. 脂漏性皮膚炎とMalassezia. In : 第2回Dermatological Mycology Club例会 記録集. 日本アクセル・シュプリンガー出版 ; 1995. p.76-84.
 
4) Gupta AK, Versteeg SG. Topical treatment of facial seborrheic dermatitis : a systematic review. Am J Clin Dermatol. 2017 ; 18 : 193-213.
PubMed
P.165 掲載の参考文献
1) Tominaga M, Ozawa S, Tengara S, et al. Intraepidermal nerve fibers increase in dry skin of acetone-treated mice. J Dermatol Sci. 2007 ; 48 : 103-11.
PubMed
2) 田尻真輔, 中山樹一郎. 乾皮症を含む皮脂欠乏性湿疹に対する持続性選択ヒスタミンh1受容体拮抗薬ロラタジンの止痒効果の検討. 西日皮. 2006 ; 68 : 683-90.
 
3) 竹村司. 皮脂欠乏性湿疹患者を対象としたロラタジンの有用性の検討. 診療と新薬. 2009 ; 46 : 911-21.
 
4) Kikuchi K, Tagami H, Japanese Cosmetic Scientist Task Force for Skin Care of Atopic Dermatitis. Noninvasive biophysical assessments of the efficacy of a moisturizing cosmetic cream base for patients with atopic dermatitis during different seasons. Br J Dermatol. 2008 ; 158 : 969-78.
PubMed
5) Kikuchi K, Nozawa K, Yamazaki N, et al. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. J Dermatol. 2019 ; 46 : 18-25.
PubMed
6) Hara M, Kikuchi K, Watanabe M, et al. Senile xerosis ; functional, morphological, and biochemical studies. J Geriatr Dermatol. 1993 ; 1 : 111-20.
 
7) 船本香里, 古橋茉里子, 仲尾次浩一, 他. 乳幼児の皮膚に関する生理学的特性. 日小児皮会誌. 2020 ; 39 : 13-21.
 
8) 川尻康晴, 須山茂子, 大原禎裕, 他. 乳幼児の皮膚生理特性 (第1報). 日小児皮会誌. 1993 ; 12 : 77-81.
 
P.169 掲載の参考文献
1) 秀道広, 森桶聡, 福永淳, 他. 蕁麻疹診療ガイドライン 2018. 日皮会誌. 2018 ; 12 : 2503-624.
 
2) Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy. 2018 ; 73 : 1393-414.
 
3) Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010 ; 125 : 676-82.
PubMed
4) 森田栄伸. In : 塩原哲夫, 他, 編. 1冊でわかる皮膚アレルギー. 文光堂 ; 2012. p.83.
 
5) ザイザル(R) 錠5 mg 添付文書.
 
6) デザレックス(R) 錠5 mg 添付文書.
 
7) 森田栄伸, 越智康之. 蕁麻疹治療における抗ヒスタミン薬の使い分け. Med Pract. 2019 ; 36 : 761-6.
Medical*Online
P.171 掲載の参考文献
1) 秀道広, 森桶聡, 福永淳, 他. 蕁麻疹診療ガイドライン 2018. 日皮会誌. 2018 ; 128 : 2503-624.
 
2) Tanaka T, Hiragun M, Hide M, et al. Analysis of primary treatment and prognosis of spontaneous urticaria. Alergol Int. 2017 ; 66 : 458-62.
 
3) Curto-Barredo L, Archilla LR, Vives GR, et al. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018 ; 98 : 641-7.
PubMed
P.174 掲載の参考文献
1) Narasimha SK, Srinivas CR, Mathew AC. Effect of topical corticosteroid application frequency on histamine-induced wheals. Int J Dermatol. 2005 ; 44 : 425-7.
PubMed
2) Vena GA, Cassano N, D'Argento V, et al. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria : a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2006 ; 154 : 353-6.
 
3) 矢村卓三, 山崎玲子. 蕁麻疹. In : 山村雄一, 他, 責任編集. 現代皮膚科学体系 13. 中山書店 ; 1980. p.201-76.
 
4) Henz BM, Zuberbier T, Monroe E. Urticaria therapy. In : Henz BM, et al, editors. Urticaria, Berlin : Springer ; 1998. p.161-81.
 
5) 室田浩之. 塗り薬は効くのか? In : 秀道広, 他. じんましん最前線. メディカルレビュー社 ; 2007. p.142.
 
6) Grattan CEH, Humphreys F. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee : Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol. 2007 ; 157 : 1116-23.
 
7) Dickson MC, Walker A, Grattan C, et al. Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria : results of a phase 1a/b randomised double-blind placebo-controlled study. Br J Clin Pharmacol. 2021 ; 87 : 4797-808.
PubMed
P.177 掲載の参考文献
1) Church MK, Kolkhir P, Metz M, et al. The role and relevance of mast cells in urticaria. Immunol Rev. 2018 ; 282 : 232-47.
PubMed
2) Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2017 ; 142 : 876-82.
PubMed
3) Yanase Y, Matsuo Y, Kawaguchi T, et al. Activation of human peripheral basophils in response to high IgE antibody concentrations without antigens. Int J Mol Sci. 2018 ; 20 : 45.
 
4) Deza G, Bertolin-Colilla M, Pujol RM, et al. Basophil FcepsilonRI expression in chronic spontaneous urticaria : a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017 ; 97 : 698-704.
PubMed
5) Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018 ; 73 : 705-12.
PubMed
6) 秀道広. 慢性蕁麻疹の診断と治療への洞察. アレルギー. 2021 ; 70 : 936-41.
Medical*Online
P.180 掲載の参考文献
1) Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 ; 26 : 2006-12.
PubMed
2) Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 ; 381 : 303-12.
PubMed
3) 有害事象共通用語規準 v5.0 日本語訳 JCOG版. 2018.
 
4) Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park). 2004 ; 18 : 1161-8, 1173 ; discussion 1173-6, 1181-4.
 
5) Wolf SL, Qin R, Menon SP, et al. North Central Cancer Treatment Group Study N05C5. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome. J Clin Oncol. 2010 ; 28 : 5182-7.
 
6) 須藤剛, 石山廣志朗, 矢吹皓, 他. 大腸癌術後補助化学療法としてのCapecitabine投与例の有害事象の検討 手足症候群対策を中心に. 癌と化療. 2010 ; 37 : 1729-33.
Medical*Online
7) 藤井千賀, 阿南節子, 藤野美佐子, 他. Capecitabine投与患者における手足症候群のマネジメント. 癌と化療. 2008 ; 35 : 1357-60.
Medical*Online
8) Ren Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015 ; 33 : 894-900.
PubMed
9) 小林美沙樹, 小田中みのり, 鈴木真也, 他. ソラフェニブによる手足症候群に対する尿素配合軟膏の予防投与の有効性. 医療薬. 2015 ; 41 : 18-23.
Medical*Online
10) 志田敏宏, 加藤智幸, 冨田善彦, 他. マルチキナーゼ阻害剤の手足症候群発現に対する尿素軟膏およびヘパリン類似物質含有軟膏塗布による予防効果の比較. 日病薬師会誌. 2013 ; 49 : 1293-7.
Medical*Online
11) Gerbrecht BM. Current Canadian experience with capecitabine : partnering with patients to optimize therapy. Cancer Nurs. 2003 ; 26 : 161-7.
PubMed
P.184 掲載の参考文献
1) LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis) : classification, subsets and pathogenesis. J Rheumatol. 1988 ; 15 : 202-5.
PubMed
2) 浅野善英, 神人正寿, 川口鎮司, 他. 全身性強皮症 診断基準・重症度分類・診療ガイドライン委員会. 全身性強皮症 診断基準・重症度分類・診療ガイドライン. 日皮会誌. 2016 ; 126 : 1831-96.
 
3) 桑名正隆. 強皮症の皮膚硬化に対する治療-現状と将来展望-. リウマチ科. 2012 ; 48 : 385-93.
 
4) Sharada B, Kumar A, Kakker R, et al. Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int. 1994 ; 14 : 91-4.
PubMed
5) Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol. 2004 ; 22 (Suppl 33) : S87-9.
 
6) Steen VD, Medsger TA Jr. The palpable tendon friction rub : an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum. 1997 ; 40 : 1146-51.
PubMed
P.187 掲載の参考文献
1) Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis : a multicenter cross-sectional study. Arch Dermatol. 2011 ; 147 : 391-8.
PubMed
2) Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020 ; 72 : 488-98.
PubMed
3) Awaji K, Asano Y, Fukui Y, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis-longitudinal course of anti-MDA5 antibody titer in two cases. Journal of Cutaneous Immunology and Allergy. First published : 29 March 2021. https://doi.org/10.1002/cia2.12169
 
P.190 掲載の参考文献
1) Ise S, Ofuji S. Subcorneal pustular dermatosis ; a follicular variant? Arch Dermatol. 1965 ; 92 : 169-71.
 
2) 宮地良樹. 好酸球性膿疱性毛包炎. In : 玉置邦彦, 他, 編. 最新皮膚科学体系 6巻. 中山書店 ; 2002. p.244-9.
 
3) 野村尚史, 松村由美, 椛島健治, 他. 太藤病の病型. 皮病診療. 2013 ; 35 : 129-36.
 
4) Nomura T, Katoh M, Yamamoto Y, et al. Eosinophilic pustular folliculitis : a proposal of diagnostic and therapeutic algorithms. J Dermatol. 2016 ; 43 : 1301-6.
PubMed
5) Yamamoto Y, Nomura T, Kabashima K, et al. Clinical epidemiology of eosinophilic pustular folliculitis : results from a nationwide survey in Japan. Dermatology. 2015 ; 230 : 87-92.
PubMed
6) 野村尚史. 好酸球性膿疱性毛包炎-日本の現状は? In : 宮地良樹, 編. そこが知りたい 達人が伝授する日常皮膚診療の極意と裏ワザ. 全日本病院出版会 ; 2016. p.366-9.
 
7) 野村尚史. 好酸球性膿疱性毛包炎. In : 宮地良樹, 編. 皮膚疾患ベスト治療 臨床決断の戦略・エビデンス. 学研メディカル秀潤社 ; 2016. p.99-106.
 
8) 佐伯秀久, 大矢幸弘, 古田淳一, 他. アトピー性皮膚炎診療ガイドライン 2021. 日皮会誌. 2021 ; 131 : 2691-777.
 
9) 野村尚史. 好酸球性膿疱性毛包炎の診断と治療のアルゴリズム. 日皮会誌. 2019 ; 129 : 149-55.
 
P.196 掲載の参考文献
1) Nakagawa H, Niiro H, Oitaki K, et al. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis : efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016 ; 81 : 44-52.
 
2) Reich K, Armstrong AM, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE) : results from a phase 3, randomised controlled trial. Lancet. 2019 ; 394 : 831-9.
 
3) Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge) : results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021 ; 184 : 50-9.
PubMed
4) 朝比奈昭彦, 梅澤慶紀, 大槻マミ太郎, 他. 乾癬性関節炎診療ガイドライン 2019. 日皮会誌. 2015 ; 125 : 2023-48.
 
5) Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis : results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab) -controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 ; 76 : 79-87.
PubMed
6) Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis : a population-based cohort study in the U. K. Br J Dermatol. 2010 ; 163 : 586-92.
 
7) Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy : results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 ; 77 : 228-33.
PubMed
8) Clowse ME, Forger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk : results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 ; 76 : 1890-6.
PubMed
P.200 掲載の参考文献
1) Ferreira C, Azevedo A, Nogueira M, et al. Management of psoriasis in pregnancy - a review of the evidence to date. Drugs Context. 2020 ; 9 : 2019-11-6.
PubMed
2) Owczarek W, Walecka I, Lesiak A, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation : a review of current clinical guidelines. Postepy Dermatol Alergol. 2020 ; 37 : 821-30.
PubMed
3) De Simone C, Calabrese L, Balato A, et al. Psoriasis and its management in women of childbearing age : tools to increase awareness in dermatologists and patients. G Ital Dermatol Venereol. 2020 ; 155 : 434-40.
PubMed
4) 村川洋子, 齋藤滋. リウマチ性疾患のガイドライン 全身性エリテマトーデス, 関節リウマチ, 若年性特発性関節炎や炎症性腸疾患罹患女性患者の妊娠, 出産を考えた治療指針. 日本リウマチ学会総会・学術集会プログラム・抄録集. 2019. p.234. https://ra-ibd-sle-pregnancy.org/doctor_toward/index.html (2022年5月閲覧)
 
5) Kimball AB, Guenther L, Kalia S, et al. Pregnancy outcomes in women with moderate-to-severe psoriasis from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2021 ; 157 : 301-6.
PubMed
6) Russo R, Gasparini G, Cozzani E, et al. Considerations on inhibition of IL-23 in psoriatic women of childbearing potential. Dermatol Ther. 2021 ; 8 : e14931.
 
7) Liu N, Zhu L, Cheng Y, et al. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab : a case report. Acta Derm Venereol. 2020 ; 100 : adv00251.
PubMed
8) Cheent K, Nolan J, Shariq S, et al. Case report : fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010 ; 4 : 603-5.
 
9) Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017 ; 3 : 21-5.
PubMed
10) Malek A, Sager R, Schneider H. Maternal-fetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy. Am J Reprod Immunol. 1994 ; 32 : 8-14.
PubMed
11) Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy : results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 ; 77 : 228-33.
PubMed
12) Clowse ME, Forger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk : results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 ; 76 : 1890-6.
PubMed
P.203 掲載の参考文献
1) Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis : a phase 3 randomized clinical trial. JAMA Dermatol. 2020 ; 156 : 649-58.
PubMed
2) Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment : results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 ; 76 : 418-31.
 
3) Umezawa Y, Torisu-Itakura H, Morisaki Y, et al. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients : impact of treatment withdrawal and retreatment of ixekizumab. J Eur Acad Dermatol Venereol. 2019 ; 33 : 568-76.
PubMed
P.206 掲載の参考文献
1) 佐藤俊宏. とっておきの1症例! (3) -2年間の投与の後に急速に改善した例-. J Visual Dermatol. 2019 ; 18 : 1021-3.
 
2) Kishimoto M, Komine M, Kamiya K, et al. Drug survival of apremilast in a real-world setting. J Dermatol. 2019 ; 46 : 615-7.
 
3) Dozier L, Bartos G, Kerdel F. Apremilast and psoriasis in the real world : a retrospective case series. J Am Acad Dermatol. 2020 ; 83 : 221-2.
 
4) Augustin M, Kleyn CE, Conrad C, et al. Characteristics and outcomes of patients treated with apremilast in the real world : results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021 ; 35 : 123-34.
PubMed
5) Bagel J, Nelson E, Keegan BR. Apremilast and narrowband ultraviolet-B combination therapy for treating moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2017 ; 16 : 957-62.
PubMed
6) Takamura S, Sugai S, Taguchi R, et al. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue. J Dermatol. 2020 ; 47 : 290-4.
PubMed
7) Ighani A, Georgakopoulos JR, Walsh S, et al. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice : a Canadian multicenter retrospective study. J Am Acad Dermatol. 2018 ; 78 : 623-6.
 
P.208 掲載の参考文献
1) Lebwohl M, Herrmann LG. Impaired skin barrier function in dermatologic disease and repair with moisturization. Cutis. 2005 ; 76 (6 Suppl) : 7-12.
 
2) Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003 ; 4 : 771-88.
PubMed
3) Proksch E, Lachapelle JM. The management of dry skin with topical emollients--recent perspectives. J Dtsch Dermatol Ges. 2005 ; 3 : 768-74.
PubMed
4) Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008 ; 26 : 380-6.
PubMed
5) Draelos ZD. Moisturizing cream ameliorates dryness and desquamation in participants not receiving topical psoriasis treatment. Cutis. 2008 ; 82 : 211-6.
 
6) Meyer N, Paul C, Feneron D, et al. Psoriasis : an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010 ; 24 : 1075-82.
PubMed
7) Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol. 2009 ; 10 Suppl 1 : 7-12.
 
8) Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol. 2008 ; 21 : 75-80.
PubMed
9) Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001 ; 76 : 943-9.
PubMed
10) Wohlrab W. Recovery rate of externally administered glucocorticoids on the skin surface. Dermatol Monatsschr. 1986 ; 172 : 615-9.
PubMed
11) Ghali FE. Improved clinical outcomes with moisturization in dermatologic disease. Cutis. 2005 ; 76 (6 Suppl) : 13-8.
 
12) Watsky KL, Freije L, Leneveu MC, et al. Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis. 1992 ; 50 : 383-6.
PubMed
13) Cassano N, Mantegazza R, Battaglini S, et al. Adjuvant role of a new emollient cream in patients with palmar and/or plantar psoriasis : a pilot randomized open-label study. G Ital Dermatol Venereol. 2010 ; 145 : 789-92.
PubMed
14) Tanghetti EA, Tazarotene Stable Plaque Psoriasis Trial Study Group. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis. 2000 ; 66 (6 Suppl) : 4-11.
 
15) Seite S, Khemis A, Rougier A, et al. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis. Exp Dermatol. 2009 ; 18 : 1076-8.
PubMed
16) Comaish JS, Greener JS. The inhibiting effect of soft paraffin on the Kobner response in psoriasis. Br J Dermatol. 1976 ; 94 : 195-200.
PubMed
P.213 掲載の参考文献
1) 川田暁. 肝斑治療の現状. 皮病診療. 2010 ; 32 : 427-33.
 
2) 川島眞, 堀内祐紀, 山本有紀, 他. 肝斑の治療. Bella Pelle. 2019 ; 4 : 80-7.
Medical*Online
3) 堀内祐紀, 山田美奈, 千葉真美, 他. 肝斑に対するレーザートーニングの有用性の検討. Aesthetic Dermatology. 2018 ; 28 : 307-18.
 
4) Pandya AG, Hynan LS, Bhore R, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011 ; 64 : 78-83, 83.e1-2.
 
5) 根岸圭, 竹内かおり, 櫛方暢晴, 他. IPLを用いた肝斑の複合治療についての検討. 日美外報. 2007 ; 29 : 149-55.
 
6) 葛西健一郎. 低フルエンスQ-switched Nd : YAGレーザー治療 (レーザートーニング) による肝斑増悪症例に対する治療経験. 形成外科. 2017 ; 60 : 217-22.
Medical*Online
7) Sugawara J, Kou S, Kou S, et al. Influence of the frequency of laser toning for melasma on occurrence of leukoderma and its early detection by ultraviolet imaging. Lasers Surg Med. 2015 ; 47 : 161-7.
PubMed
8) Kang HY, Bahadran P, Suzuki I, et al. In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution. Exp Dermatol. 2010 ; 19 : e228-33.
 
9) 船坂陽子. 学会合同美容医療診療指針 (令和元年度厚生労働科学特別研究事業) 肝斑にレーザーやIPLは有効か? 日本美容外科学会会報. 2021 ; 43 : 53.
 
10) Halachmi S, Haedersdal M, Lapidoth M, et al. Melasma and laser treatment : an evidenced-based analysis. Lasers Med Sci. 2014 ; 29 : 589-98.
PubMed
11) Passeron T, Genedy R, Salah L, et al. Laser treatment of hyperpigmented lesions : position statement of the European Society of Laser in Dermatology. J Eur Acad Dermatol Venereol. 2019 ; 33 : 987-1005.
PubMed
P.216 掲載の参考文献
1) Kang WH, Yoon KH, Lee ES, et al. Melasma : histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002 ; 146 : 228-37.
PubMed
2) Tse TW, Hui E. Tranexamic acid : an important in the treatment of melasma. J Cosmet Dermatol. 2013 ; 12 : 57-66.
PubMed
3) Bala HR, Lee S, Wong C, et al. Oral tranexamic acid for the treatment of melasma : a review. Am J Dermatol Surg. 2018 ; 44 : 814-25.
 
4) Cho HH, Choi M, Cho S, et al. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd : YAG laser. J Dermatolog Treat. 2013 ; 24 : 292-6.
PubMed
5) Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma : a retrospective analysis. J Am Acad Dermatol. 2016 ; 75 : 385-92.
 
6) Sanadi RM, Deshmukh RS. The effect of vitamin C on melanin pigmentation-a systematic review. J Oral Maxillofac Pathol. 2020 ; 24 : 374-82.
PubMed
P.222 掲載の参考文献
1) 中瀬恵亮. 薬剤耐性アクネ菌 最近の話題. J Visual Dermatol. 2021 ; 20 : 133-5.
 
2) Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne- update 2016- short version. J Eur Acad Dermatol Venereol. 2016 ; 30 : 1261-8.
PubMed
3) Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 ; 74 : 945-73.
PubMed
4) Hayashi N, Akamatsu H, Iwatsuki K, et al. Japanese Dermatological Association Guidelines : Guidelines for the treatment of acne vulgaris 2017. J Dermatol. 2018 ; 45 : 898-935.
PubMed
5) 厚生労働省保険局医療課. 医薬品の適応外使用に係る保険診療上の取扱いについて. https://www.ajha.or.jp/topics/admininfo/pdf/2018/181001_1.pdf (2022年5月閲覧)
 
P.224 掲載の参考文献
1) 医薬食品局審査管理課. ベピオゲル審議結果報告書. 平成26年11月26日. https://www.pmda.go.jp/drugs/2014/P201400176/730155000_22600AMX01392_A100_1.pdf (2022年5月閲覧)
 
2) 川島眞, 宮地良樹. 体幹部の尋常性ざ瘡に対する過酸化ベンゾイルゲル2.5%の有用性の検討. 先端医療と健美容. 2017 ; 4 : 24-34.
 
P.226 掲載の参考文献
1) Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother. 1999 ; 43 : 1533-41.
PubMed
2) Paul JC, Pieper BA. Topical metronidazole for the treatment of wound odor : a review of the literature. Ostomy Wound Manage. 2008 ; 54 : 18-27 ; quiz 28-9.
 
3) Finlay IG, Bowszyc J, Ramlau C, et al. The effect of topical 0.75% metronidazole gel on malodorous cutaneous ulcers. J Pain Symptom Manage. 1996 ; 11 : 158-62.
 
4) van Zuuren EJ, Kramer SF, Carter BR, et al. Effective and evidence-based management strategies for rosacea : summary of a Cochrane systematic review. Br J Dermatol. 2011 ; 165 : 760-81.
PubMed
5) Miyachi Y, Yamasaki K, Fujita T, et al. Metronidazole gel (0.75%) in Japanese patients with rosacea : a randomized, vehicle-controlled, phase 3 study. J Dermatol. 2022 ; 49 : 330-40.
 
P.229 掲載の参考文献
1) 坪井良治, 植木理恵, 中村元信, 他. 日本皮膚科学会円形脱毛症診療ガイドライン 2017年版. 日皮会誌. 2017 ; 127 : 2741-62.
 
2) Dainichi T, Kabashima K. Alopecia areata : what' s new in epidemiology, pathogenesis, diagnosis, and therapeutic options? J Dermatol Sci. 2017 ; 86 : 3-12.
 
3) 大日輝記. Unmet needsのある皮膚疾患治療薬の開発動向 9.4円形脱毛症. In : 宮地良樹, 他, 編. エビデンスに基づく皮膚科新薬の治療指針. 中山書店 ; 2021.
 
P.231 掲載の参考文献
1) Harcha WG, Martinez JB, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014 ; 70 : 489-98.e3
 
2) Overstreet JW, Fuh VL, Gould J, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 1999 ; 162 : 1295-300.
 
3) Samplaski MK, Lo K, Grober E, et al. Finasteride use in the male infertility population : effects on semen and hormone parameters. Fertil Steril. 2013 ; 100 : 1542-6.
PubMed
4) Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007 ; 92 : 1659-65.
 
P.234 掲載の参考文献
1) Lachgar S, Charveron M, Gall Y, et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998 ; 138 : 407-11.
PubMed
2) Han JH, Kwon OS, Chung JH, et al. Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. J Dermatol Sci. 2004 ; 34 : 91-8.
PubMed
3) Hu R, Xu F, Sheng Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia : a randomized and comparative study in Chinese patients. Dermatol Ther. 2015 ; 28 : 303-8.
PubMed
P.237 掲載の参考文献
1) Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001 ; 45 (3 Suppl) : s70-80.
 
2) Harries M, Tosti A, Bergfeld W, et al. Towards a consensus on how to diagnose and quantify female pattern hair loss-The 'Female Pattern Hair Loss Severity Index (FPHL-SI)'. J Eur Acad Dermatol Venereol. 2016 ; 30 : 667-76.
 
3) Ueki R, Tsuboi R, Ynaba Y, et al. Phototrichogram analysis of Japanease female subjects with chronic diffuse hair loss. J Investig Dermatol Symp Proc. 2003 ; 8 : 116-20.
 
4) 男性型および女性型脱毛症診療ガイドライン作成委員会. 男性型および女性型脱毛症診療ガイドライン 2017年版. 日皮会誌. 2017 ; 127 : 2763-77.
 
5) 岩下聡, 宮川春菜, 上野友美, 他. 閉経後女性における毛髪とエクオール産生能の関係に関する観察研究. Aesthe Derma. 2020 ; 30 : 8-17.
 
P.240 掲載の参考文献
1) 齋藤昌孝. 爪母温存爪甲側縁楔状切除術. In : 高山かおる, 他, 編. 足爪治療マスターBOOK. 全日本病院出版会 ; 2020. p.170-3.
 
P.243 掲載の参考文献
1) 齋藤昌孝. 巻き爪マイスター(R). In : 高山かおる, 他, 編. 足爪治療マスターBOOK. 全日本病院出版会 ; 2020. p.132-7.
 
P.247 掲載の参考文献
1) Bauland CG, Luning TH, Smit JM, et al. Untreated hemangiomas : growth pattern and residual lesions. Plast Reconstr Surg. 2011 ; 127 : 1643-8.
PubMed
2) Baselga E, Roe E, Coulie J, et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol. 2016 ; 152 : 1239-43.
PubMed
3) Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019 ; 143 : e20183475.
PubMed
4) 難治性血管腫・血管奇形・リンパ管腫・リンパ管腫症および関連疾患についての調査研究班. 血管腫・血管奇形・リンパ管奇形診療ガイドライン 2017 第2版. 2017.
 
5) Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015 ; 372 : 735-46.
PubMed
6) Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma : a systematic review and meta-analysis. Plast Reconstr Surg. 2013 ; 131 : 601-13.
PubMed
7) Xu S, Jia R, Ge S, et al. Treatment of periorbital infantile haemangiomas : a systematic literature review on propranolol or steroids. J Paediatr Child Health. 2014 ; 50 : 271-9.
PubMed
8) Batta K, Goodyear HM, Moss C, et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas : results of a 1-year analysis. Lancet. 2002 ; 360 : 521-7.
PubMed
9) Kagami S, Kuwano Y, Shibata S, et al. Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. Eur J Pediatr. 2013 ; 172 : 1521-6.
PubMed
10) Puttgen K, Lucky A, Adams D, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016 ; 138 : e20160355.
PubMed
11) Zaher H, Rasheed H, Esmat S, et al. Propranolol and infantile hemangiomas : different routes of administration, a randomized clinical trial. Eur J Dermatol. 2013 ; 23 : 646-52.
PubMed
12) 乳児血管腫専門医セミナー SMILE3. ヘマンジオルのリスクと対策. 2019.
 
13) 桑野嘉弘. 乳児血管腫の治療. 皮病診療. 2019 ; 41 : 900-6.
 
14) Wang O, Xiang B, Chen S, et al. Efficacy and safety of oral atenolol for the treatment of infantile haemangioma : a systematic review. Australas J Dermatol. 2019 ; 60 : 181-5.
 
15) Carnovale C, Gringeri M, Battini V, et al. Beta-blocker-associated hypoglycaemia : new insights from a real-world pharmacovigilance study. Br J Clin Pharmacol. 2021 ; 87 : 3320-31.
PubMed
16) Coulie J, Maude C, Moniotte S. Has propranolol eradicated the need for surgery in the management of infantile hemangioma? Plast Reconstr Surg. 2015 ; 136 (4 Suppl) : 154.
 
17) Lopez-Gutierrez JC. Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol : overview of single-center experience from La Paz Hospital, Madrid. Eur J Pediatr. 2019 ; 178 : 1-6.
 
P.250 掲載の参考文献
1) Kagami S, Kuwano Y, Shibata S, et al. Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. Eur J Pediatr. 2013 ; 172 : 1521-6.
PubMed
2) Kagami S, Kaneko M, Katori T. Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol. J Dermatol. 2018 ; 45 : 719-22.
PubMed
3) Reddy KK, Blei F, Brauer JA, et al. Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. Dermatol Surg. 2013 ; 39 : 923-33.
PubMed
P.253 掲載の参考文献
1) Ogawa R, Akita S, Akaishi S, et al. Diagnosis and treatment of keloids and hypertrophic scars-Japan scar workshop consensus document 2018. Burns Trauma. 2019 ; 7 : 39.
PubMed
2) Chong Y, Kim CW, Kim YS, et al. Complete excision of proliferating core in auricular keloids significantly reduces local recurrence : a prospective study. J Dermatol. 2018 ; 45 : 139-44.
 
3) Nast A, Gauglitz G, Lorenz K, et al. S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids) -update 2020. J Dtsch Dermatol Ges. 2021 ; 19 : 312-27.
 
4) Berman B, Nestor MS, Gold MH, et al. A retrospective registry study evaluating the long-term efficacy and safety of superficial radiation therapy following excision of keloid scars. J Clin Aesthet Dermatol. 2020 ; 13 : 12-6.
 
5) Shin JY, Lee JW, Roh SG, et al. A comparison of the effectiveness of triamcinolone and radiation therapy for ear keloids after surgical excision : a systematic review and meta-analysis. Plast Reconstr Surg. 2016 ; 137 : 1718-25.
PubMed
6) Siotos C, Uzosike AC, Hong H, et al. Keloid excision and adjuvant treatments : a network meta-analysis. Ann Plast Surg. 2019 ; 83 : 154-62.
PubMed
P.255 掲載の参考文献
1) 安齋眞一, 梅林芳弘, 勝俣範之, 他. 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日皮会誌. 2020 ; 130 : 2501-33.
 
2) Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis : a review. Br J Dermatol. 2017 ; 177 : 350-8.
PubMed
3) Berry K, Butt M, Kirby JS. Influence of information framing on patient decisions to treat actinic keratosis. JAMA Dermatol. 2017 ; 153 : 421-6.
PubMed
4) 足立勇博, 漆田玲子, 手嶋司, 他. 日光角化症に対するイミキモドの使用成績調査. Therapeutic Research. 2018 ; 39 : 441-52.
Medical*Online
P.258 掲載の参考文献
1) 吉野公二, 清原隆宏, 逆瀬川純子, 他. 皮膚悪性腫瘍ガイドライン 第3版 乳房外パジェット病診療ガイドライン 2021. 日皮会誌. 2021 ; 131 : 225-44.
 
2) 熊野公子, 村田洋三. II-5 乳房外Paget病の発生部位. カラーアトラス乳房外Paget病-その素顔-. 全日本病院出版会 ; 2015. p.22-4.
 
P.261 掲載の参考文献
1) Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010 ; 116 : 1757-66.
PubMed
2) Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 ; 366 : 2443-54.
PubMed
3) Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 ; 515 : 568-71.
PubMed
4) Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014 ; 371 : 2189-99.
PubMed
5) Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 ; 350 : 1084-9.
PubMed
6) Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 ; 372 : 2509-20.
PubMed
7) Nonomura Y, Otsuka A, Nakashima C, et al. Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients. Oncoimmunology. 2016 ; 5 : e1248327.
PubMed
8) Iwama S, De Remigis A, Callahan M, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014 ; 6 : 230ra45.
PubMed
9) Kanameishi S, Otsuka A, Nonomura Y, et al. Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol. 2016 ; 27 : 546-7.
 
10) Arakawa A, Siewert K, Stohr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015 ; 212 : 2203-12.
PubMed
11) Nonomura Y, Otsuka A, Ohtsuka M, et al. ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab. J Eur Acad Dermatol Venereol. 2017 ; 31 : e100-1.
PubMed
P.263 掲載の参考文献
1) 清原祥夫, 吉川周佐, 藤原規広, 他. 皮膚悪性腫瘍におけるSentinel Node Navigation Surgery. 癌と化療. 2005 ; 32 : 1191-4.
Medical*Online
2) Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients : two-step prognostic indicators of survival. J Clin Oncol. 2006 ; 24 : 4464-71.
PubMed
3) Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004 : 22 : 3677-84.
PubMed
4) Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017 ; 376 : 2211-22.
 
5) 中村泰大, 浅井純, 井垣浩, 他. 皮膚悪性腫瘍ガイドライン 第3版 メラノーマ診療ガイドライン 2019. 日皮会誌. 2019 ; 129 : 1759-843.
 
6) Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014 ; 370 : 599-609.
PubMed
7) Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017 ; 377 : 1824-35.
 
8) Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017 ; 377 : 1813-23.
PubMed
9) Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018 ; 378 : 1789-801.
PubMed
P.267 掲載の参考文献
1) Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019 ; 381 : 626-36.
PubMed
2) Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019 ; 381 : 1535-46.
PubMed
3) Ascieto PA, Mandala M, Ferrucci PF, et al. First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). Ann Oncol. 2020 ; 31 (suppl 4) : S1142-215.
 
4) Desai A, Ugorji R, Khachemoune A. Acral melanoma foot lesions. Part 1 : epidemiology, aetiology, and molecular pathology. Clin Exp Dermatol. 2017 ; 42 : 845-8.
PubMed
5) Kiyohara Y, Uhara H, Ito Y, et al. Safety and efficacy of nivolumab in Japanese patients with malignant melanoma : an interim analysis of a postmarketing surveillance. J Dermatol. 2018 ; 45 : 408-15.
PubMed
6) D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma : a pooled analysis. J Clin Oncol. 2017 ; 35 : 226-35.
PubMed
7) Nakamura Y, Namikawa K, Yoshino K, et al. Anti-PD1 checkpoint inhibitor therapy in acral melanoma : a multicenter study of 193 Japanese patients. Ann Oncol. 2020 ; 31 : 1198-206.
PubMed
8) Takahashi A, Namikawa K, Nakano E, et al. Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma. J Dermatol. 2020 ; 47 : 257-64.
PubMed
9) Fujisawa Y, Ito T, Kato H, et al. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma : an analysis of 112 cases. Eur J Cancer. 2021 ; 145 : 210-20.
PubMed
P.273 掲載の参考文献
1) Asada H, Nagayama K, Okazaki A, et al. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. J Dermatol Sci. 2013 ; 69 : 243-9.
PubMed
2) Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 ; 352 : 2271-84.
PubMed
3) Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 ; 372 : 2087-96.
PubMed
4) Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 ; 375 : 1019-32.
PubMed
P.276 掲載の参考文献
1) McKendrick MW, Care CC, Kudesia G, et al. Is VZV reactivation a common cause of unexplained unilateral pain? Results of a prospective study of 57 patients. J Infect. 1999 ; 39 : 209-12.
PubMed
2) Gilden D, Cohrs RJ, Mahalingam R, et al. Neurological disease produced by varicella zoster virus reactivation without rash. Curr Top Microbiol Immunol. 2010 ; 342 : 243-53.
PubMed
3) Imafuku S, Dormal G, Goto Y, et al. Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions : results from a claims database cohort study, from 2005 to 2014. J Dermatol. 2020 ; 47 : 236-44.
PubMed
4) Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 ; 58 : i34-42.
PubMed
5) 松代直樹, 北村江理, 桐広樹, 他. 『トリアージ10点法』とElectroneurography (ENoG) の関係 VZV 関連性の顔面神経麻痺に関して. Facial Nerv Res. 2016 ; 36 : 164-6.
Medical*Online
P.280 掲載の参考文献
1) Toyama N, Shiraki K, Miyazaki Dermatologist Society. Universal varicella vaccination increased the incidence of herpes zoster in the child-rearing generation as its short-term effect. J Dermatol Sci. 2018 ; 92 : 89-96.
PubMed
2) Australian Government Department of Health and Ageing Therapeutic Goods Administration. http://www.tga.gov.au/hp/medicines-pregnancy.htm (2022年5月閲覧)
 
3) Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010 ; 304 : 859-66.
PubMed
4) 山本剛伸. 帯状疱疹治療のアルゴリズム. Visual Dermatology. 2019 ; 18 : 886-90.
 
5) Ressel G. AAP updates statement for transfer of drugs and other chemicals into breast milk. American Academy of Pediatrics. Am Fam Physician. 2002 ; 65 : 979-80.
 
6) Sheffield JS, Fish DN, Hollier LM, et al. Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol. 2002 ; 186 : 100-2.
PubMed
7) LactMed (Drugs and Lactation Database). https://www.ncbi.nlm.nih.gov/books/NBK501922/ (2022年5月閲覧)
 
8) Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Child Adolesc Psychiatr Clin N Am. 2015 ; 24 : 1-20.
PubMed
9) Norwitz ER, Greenberg JA. Antibiotics in pregnancy : are they safe? Rev Obstet Gynecol. 2009 ; 2 : 135-6.
PubMed
P.283 掲載の参考文献
1) Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (amantadine). Science. 1964 ; 144 : 862-3.
PubMed
2) De Benedittis G, Lorenzetti A. Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia : a double-blind crossover placebo-controlled study. Pain. 1996 ; 65 : 45-51.
PubMed
3) Satyaprakash AK, Tremaine AM, Stelter AA, et al. Viremia in acute herpes zoster. J Infect Des. 2009 ; 200 : 26-32.
 
P.285 掲載の参考文献
1) 川島眞. 再発型単純疱疹患者の患者背景およびQOLに関するアンケート調査. 臨医薬. 2013 ; 29 : 137-49.
Medical*Online
2) 日本性感染症学会, 編. 性感染症診断・治療ガイドライン 2020. 診断と治療社 ; 2020.
 
3) 川島眞, 加藤俊之, 藤井千恵, 他. ファムシクロビルの再発型単純疱疹患者に対する早期短期治療 (1日治療) による第III相臨床試験. 日臨皮誌. 2018 ; 35 : 488-96.
 
P.288 掲載の参考文献
1) 江川清文. 尋常性疣贅 (1) 概念・定義の変遷と基本的臨床像. In : 江川清文, 編著. 疣贅 (いぼ) のみかた, 治療のしかた. 学研メディカル秀潤社 ; 2017. p.56-63.
 
2) Bruggink SC, Gussekloo J, de Koning MNC, et al. HPV type in plantar warts influences natural course and treatment response : secondary analysis of a randomised controlled trial. J Clin Virol. 2013 ; 57 : 227-32.
 
3) Mulhem E, Pinelis S. Treatment of nongenital cutaneous warts. Am Fam Physician. 2011 ; 84 : 288-93.
PubMed
4) Sonnex TS, Camp RDR. The treatment of recalcitrant viral warts with high dose cryosurgery under local anesthesia. Br J Dermatol. 1988 ; 119 (s33) : 38-9.
 
5) Bruggink SC, Gussekloo J, Berger MY, et al. Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care : randomized controlled trail. CMAJ. 2010 ; 82 : 1624-30.
 
6) Kwok CS, Gibbs S, Bennett C, et al. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012 Sep 12 ; CD001781.
PubMed
7) 渡辺大輔, 五十嵐敦之, 江川清文, 他. 尋常性疣贅診療ガイドライン 2019 (第1版). 日皮会誌. 2019 ; 129 : 1265-92.
 
8) 江川清文. ウイルス性疣贅. 皮膚臨床. 2003 ; 45 : 1467-73.
 
9) 江川清文. 疣贅治療総論. In : 江川清文, 編著. 疣贅 (いぼ) のみかた, 治療のしかた. 学研メディカル秀潤社 ; 2017. p.186-99.
 
10) Larsen PO, Laurberg G. Cryotherapy of viral warts. J Derm Treatment. 1996 ; 7 : 29-31.
 
11) Bunney MH, Nolan MW, Williams DA. An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol. 1976 ; 94 : 667-79.
PubMed
12) Berth-Jones J, Hutchinson PE. Modern treatment of warts : cure rates at 3 and 6 months. Br J Dermatol. 1992 ; 127 : 262-5.
PubMed
13) Berth-Jones J, Bourke J, Eglitis H, et al. Value of a second freeze-thaw cycle in cryotherapy of common warts. Br J Dermatol. 1994 ; 131 : 883-6.
PubMed
14) 江川清文. 液体窒素凍結療法-総論-. In : 江川清文, 編著. 疣贅 (いぼ) のみかた, 治療のしかた. 学研メディカル秀潤社 ; 2017. p.200-7.
 
P.291 掲載の参考文献
1) 竹村司, 大熊一朝, 高田任康. 伝染性軟属腫の自然治癒. 皮病診療. 1983 ; 5 : 668-70.
 
2) 馬場直子. 皮膚感染症-伝染性軟属腫ととびひ. 小児内科. 2019 ; 51 : 1456-9.
Medical*Online
P.293 掲載の参考文献
1) Watanabe S, Ohnishi T, Yuasa A, et al. The first nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan. J Infect Chemother. 2017 ; 23 : 503-11.
PubMed
2) Sasai N, Nakaminami H, Iwasaki M, et al. Clonal change of methicillin-resistant Staphylococcus aureus isolated from patients with impetigo in Kagawa, Japan. J Dermatol. 2019 ; 46 : 301-7.
PubMed
3) JAID/JSC感染症治療ガイド・ガイドライン作成委員会. JAID/JSC感染症治療ガイド 2019. 日本感染症学会, 日本化学療法学会 ; 2019. p.185-7.
 
4) 山崎修. 皮膚感染症など 伝染性膿痂疹・ブドウ球菌性熱傷様皮膚症候群・多発性汗腺膿瘍. 小児診療. 2019 ; 82 : 1437-42.
 
5) 佐藤ミカ, 荒田次郎, 山崎修, 他. 水疱性膿痂疹から分離された黄色ブドウ球菌のホスホマイシン感受性および治療経験-2004年～2005年の統計. 臨皮. 2006 ; 60 : 752-6.
 
6) 常深祐一郎, 藤川晃, 岸田 諭, 他. オゼノキサシン油性クリーム剤の安全性, 有効性および細菌学的効果に関する検討-1 歳以上の伝染性膿痂疹患者を対象とした一般臨床試験の成績-. 日小皮会誌. 2021 ; 40 : 27-36.
 
7) Nakaminami H, Noguchi N, Ikeda M, et al. Molecular epidemiology and antimicrobial susceptibilities of 273 exfoliative toxin-encoding-gene-positive Staphylococcus aureus isolates from patients with impetigo in Japan. J Med Microbiol. 2008 ; 57 : 1251-8.
PubMed
P.296 掲載の参考文献
1) Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol. 1976 ; 95 : 323-8.
PubMed
2) Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012 Jan 18 ; 1 (1) : CD003261.
 
3) 坪井良治. 伝染性膿痂疹を3日間で治す方法. Derma. 2005 ; 102 : 138-42.
 
4) 浅井寿子. アンケート特集 とびひに対する治療方針 私はこうしている. 皮病診療. 2001 ; 23 : 621-2.
 
5) 池田政身. 細菌感染を伴う湿疹に抗菌薬を使うべきではない. Visual Dermatol. 2004 ; 3 : 988-9.
 
6) JAID/JSC 感染症治療ガイド・ガイドライン作成委員会. JAID/JSC 感染症治療ガイド2019. 日本感染症学会, 日本化学療法学会. 2019. p.185-7.
 
P.299 掲載の参考文献
1) 日野治子. 抗菌外用薬をどう使うか. Derma. 2007 ; 132 : 62-9.
 
2) 濱崎せり, 佐々木りか子. 当科における最近の小児の皮膚細菌感染症についての検討. 日小皮会誌. 2000 ; 19 : 189-94.
 
3) 岩木真生, 野口雅久, 中南秀将, 他. 皮膚感染症関連菌に対するゲンタマイシンの抗菌力と突然変異耐性菌出現頻度. Yakugaku Zasshi. 2011 ; 131 : 1653-9.
Medical*Online
4) 宿輪哲生, 石川博士, 佐藤伸一. MRSA伝染性膿痂疹の薬剤感受性及び治療的検討. 西日皮膚. 2006 ; 68 : 175-8.
 
5) 神崎寛子, 秋山尚範, 金本昭紀子, 他. フシジン酸耐性黄色ブドウ球菌の急増. 日皮会誌. 1989 ; 99 : 507-10.
 
6) 医薬品インタビューフォーム : ゲンタシン (R) 軟膏0.1%, ゲンタシン (R) クリーム0.1%, ゲンタマイシン硫酸塩製剤. 2017年12月改訂.
 
7) 池田政身. 伝染性膿痂疹-最新の動向. 日臨皮医誌. 2009 ; 26 : 458-62.
 
8) Nakaminami H, Ozawa K, Sasai N, et al. Current status of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus isolated from patients with skin and soft tissue infections in Japan. J Dermatol. 2020 ; 47 : 1280-6.
PubMed
P.301 掲載の参考文献
1) 伊藤孝明. 深部静脈血栓症後遺症. デルマ. 2019 ; 286 : 9-16.
 
2) Webb E, Neeman T, Bowden FJ, et al. Compression therapy to prevent recurrent cellulitis of the leg. N Engl J Med. 2020 ; 383 : 630-9.
PubMed
3) 伊藤孝明, 他. 下腿潰瘍・下肢静脈瘤診療ガイドライン. 日本皮膚科学会創傷・褥瘡・熱傷ガイドライン策定委員会, 編. 創傷・褥瘡・熱傷ガイドライン 2018. 金原出版 ; 2018. p.263-92.
 
P.304 掲載の参考文献
1) Workowski KA, Bolan GA. Sexually transmitted disease treatment guidelines, 2015. MMWR Recomm Rep. 2015 ; 64 : 34-48.
 
2) 三木吉治, 皆見紀久男, 中村準之助, 他. Amoxicillin (AMPC) による梅毒の治療とその効果. Jap J Antibiotics. 1977 ; 30 : 744-55.
 
3) 池内和彦, 福島一彰, 田中勝, 他. 梅毒に対するアモキシシリン1,500 mg 内服治療の臨床的効果. 感染症誌. 2018 ; 92 : 358-64.
 
4) Tanizaki R, Nishijima T, Aoki T, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. Clin Infect Dis. 2015 ; 61 : 177-83.
PubMed
5) 日本性感染症学会, 編. 梅毒. 性感染症 診断・治療ガイドライン 2020. 診断と治療社 ; 2020. p.46-52.
 
6) Read P, Jeoffreys N, Tagg K, et al. Azithromycin-resistant syphilis-causing strains in Sydney, Australia : prevalence and risk factors. J Clin Microbiol. 2014 ; 52 : 2776-81.
PubMed
P.307 掲載の参考文献
1) 常深祐一郎. 毎日診ている皮膚真菌症 ちゃんと診断・治療できていますか?. 南山堂 ; 2010.
 
2) 常深祐一郎. これって水虫でしょうか? J Visual Dermatol. 2020 ; 19 : 410-4.
 
3) 常深祐一郎. 皮膚真菌症 (足白癬) 日本皮膚科学会皮膚真菌症ガイドライン 2019. medicina. 2020 ; 57 : 363-7.
 
4) 常深祐一郎. 白癬菌に対する免疫応答. MB Derma. 2021 ; 310 : 33-9.
 
P.310 掲載の参考文献
1) Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis : two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013 ; 68 : 600-8.
PubMed
2) Watanabe S, Kishida H, Okubo A. Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis : a multicenter, double-blind, randomized phase III study. J Dermatol. 2017 ; 44 : 753-9.
PubMed
3) 望月隆, 坪井良治, 五十棲健, 他. 日本皮膚科学会ガイドライン 日本皮膚科学会皮膚真菌症診療ガイドライン 2019. 日皮会誌. 2019 ; 129 : 2639-73.
 
4) Iozumi K, Abe M, Ito Y, et al. Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases : a multicenter, single-arm study. J Dermatol. 2019 ; 46 : 641-51.
 
5) 佐藤友隆, 原田和俊. レセプト調査および患者アンケート調査に基づく爪白癬治療の実態把握. 日臨皮医誌. 2017 ; 34 : 742-52.
 
P.313 掲載の参考文献
1) 山口英世, 池田文昭, 伊与田貴子, 他. 皮膚真菌症患者検体から分離された皮膚糸状菌およびCandida属菌に対するravuconazole のin vitro抗真菌活性 皮膚真菌症の治療に適用承認されている2種の経口抗真菌薬との比較. Med Mycol J. 2014 ; 55 : J157-63.
 
2) 常深祐一郎, 原田和俊, 五十嵐敦之, 他. 新規アゾール系経口爪白癬治療薬ホスラブコナゾールL-リシンエタノール付加物投与時の肝機能検査アルゴリズム. Prog Med. 2019 ; 39 : 347-51.
Medical*Online
3) Saunte DML, Hare RK, Jorgensen KM, et al. Emerging terbinafine resistance in Trichophyton : clinical characteristics, squalene epoxidase gene mutations, and a reliable EUCAST method for detection. Antimicrob Agents Chemother. 2019 ; 63 : e01126-19.
 
P.316 掲載の参考文献
1) 望月隆, 古江増隆. 皮膚真菌症を究める. 皮膚科臨床アセット 4. 中山書店 ; 2011. p.112-4.
 
2) 香川三郎. 真菌症. 皮膚科MOOK 11. 金原出版 ; 1988. p.105-13.
 
3) 渡辺晋一, 望月隆, 五十棲健, 他. 皮膚真菌症診断・ガイドライン. 日皮会誌. 2009 ; 119 : 851-62.
 
4) 松田哲男. 感染性脱毛症. Derma. 1999 ; 23 : 45-52.
 
5) 望月隆, 坪井良治, 五十棲健, 他. 日本皮膚科学会皮膚真菌症診療ガイドライン 2019. 日皮会誌. 2019 ; 129 : 2639-73.
 
6) Seebacher C, Abeck D, Brasch J, et al. Tinea capitis : ringworm of the scalp. Mycoses. 2007 ; 50 : 218-26.
PubMed
7) 竹田公信, 牛上敢, 寺田麻衣子, 他. 金沢医科大学皮膚科において1998年から2007年に経験されたtinea capitisの23 例. 日皮会誌. 2011 ; 121 : 1057-61.
 
8) 竹田光信, 望月 隆. 金沢医科大学皮膚科で経験した小児のtinea capitis 21 例の検討. 日小皮会誌. 2021 ; 40 : 23-9.
 
P.319 掲載の参考文献
1) Shimoyama H, Sei Y. 2016 Epidemiological survey of dermatomycoses in Japan. Med Mycol J. 2019 ; 60 : 75-82.
PubMed
2) 望月隆, 坪井良治, 五十棲健, 他. 日本皮膚科学会皮膚真菌症診療ガイドライン 2019. 日皮会誌. 2019 ; 129 : 2639-73.
 
3) Takenaka M, Murota H, Nishimoto K. Subcutaneous phaeohyphomycosis due to Exophiala jeanselmei following renal transplantation : a case report with a published work review of phaeohyphomycosis in Japan. J Dermatol. 2020 ; 47 : 1050-3.
PubMed
4) 常深祐一郎, 原田和俊, 五十嵐敦之. 新規アゾール系経口爪白癬治療薬ホスラブコナゾールL-リシンエタノール付加物投与時の肝機能検査アルゴリズム. Prog Med. 2019 ; 39 : 347-51.
Medical*Online
5) Noguchi H, Matsumoto T, Kimura U, et al. Fosravuconazole to treat severe onychomycosis in the elderly. J Dermatol. 2021 ; 48 : 228-31.
PubMed
6) Noguchi H, Kubo M, Kashiwada-Nakamura K, et al. Topical efinaconazole : a sequential combination therapy with oral terbinafine for refractory tinea unguium. J Dermatol. 2021 ; 48 : 1401-4.
PubMed
7) Lipner SR, Joseph WS, Vlahovic TC, et al. herapeutic recommendations for the treatment of toenail onychomycosis in the US. J Drugs Dermatol. 2021 ; 20 : 1076-84.
 
P.322 掲載の参考文献
1) Chosidow O, Chastang C, Brue C, et al. Controlled study of malathion and d-phenothrin lotions for Pediculus humanus var capitis-infested schoolchildren. Lancet. 1994 ; 344 : 1724-7.
 
2) Hodgdon HE, Yoon KS, Previte DJ, et al. Determination of knockdown resistance allele frequencies in global human head louse populations using the serial invasive signal amplification reaction. Pest Manag Sci. 2010 ; 66 : 1031-40.
PubMed
3) 冨田隆史, 葛西真治, 駒形修. アタマジラミのピレスロイド系駆除剤抵抗性. 厚生労働科学研究費補助金 (新興・再興感染症研究事業) 分担研究報告書. 2011.
 
4) 伊藤誠, 山口さやか, 皆川智子, 他. 小児の難治性アタマジラミ症におけるピレスロイド抵抗性の獲得. 日小児皮会誌. 2021 ; 40 : 135-9.
 
5) Komoda M, Yamaguchi S, Takahashi K, et al. Efficacy and safety of a combination regimen of phenothrin and ivermectin lotion in patients with head lice in Okinawa. J Dermatol. 2020 ; 47 : 720-7.
PubMed
6) Yamaguchi S, Yasumura R, Okamoto Y, et al. Efficacy and safety of a dimethicone lotion in patients with pyrethroid-resistant head lice in an epidemic area, Okinawa, Japan. J Dermatol. 2021 ; 48 : 1343-9.
 
P.325 掲載の参考文献
1) 日本皮膚科学会疥癬診療ガイドライン策定委員会. 疥癬診療ガイドライン 第3版. 日皮会誌. 2015 ; 125 : 2023-48.
 
2) スミスリン(R) ローション添付文書. Kracie 2019年7月改訂 (第2版).
 
3) ストロメクトール(R) 錠3 mg 添付文書. MSD 2015年1月改訂 (第14版).
 
4) Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev. 2007 Jul 18 ; 2007 (3) : CD000320.
 
5) 日本皮膚科学会疥癬診療ガイドライン策定委員会. 疥癬診療ガイドライン第3版追補. 日皮会誌. 2018 ; 128 : 2791-801.
 
6) 石黒和守. 老人施設型疥癬-通常型から角化型に至る中間型疥癬の提唱-. 臨皮. 2018 ; 72 (増) : 162-4.
 
7) 山口さやか, 高橋健造. ピレスロイド抵抗性アタマジラミ症. 日皮会誌. 2017 ; 127 : 2305-11.
 
8) Currie BJ, Harumal P, McKinnon M, et al. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis. 2004 ; 39 : 8-12.
 
9) Terada Y, Murayama N, Ikemura H, et al. Sarcoptes scabiei var. canis refractory to ivermectin treatment in two dogs. Vet Dermatol. 2010 ; 21 : 608-12.
PubMed
10) Segura-Aguilar J, Tizabi Y. Ivermectin as a potential therapeutic in COVID-19. Clin Phamacol Transl Med. 2020 ; 4 : 160-1.
 
P.327 掲載の参考文献
1) 加藤則人, 大矢幸弘, 池田政憲, 他. アトピー性皮膚炎診療ガイドライン 2018. 日皮会誌. 2018 ; 128 : 2431-502.
 
2) 江藤隆史. ステロイド外用剤の使い方-混合の是非. 臨皮. 2001 ; 55 : 96-1327
 
4) 大井一弥, 横山 聡, 阿波勇樹, 他. タクロリムス軟膏とヘパリン類似物質製剤併用時の塗布順序と皮膚中タクロリムス濃度に関する研究. 西日皮膚. 2014 ; 76 : 127-30.
 
5) 大谷道輝, 松元美香, 野澤茜, 他. ステロイド軟膏と保湿剤の併用による塗布順序が及ぼす局所および全身性副作用への影響. 日皮会誌. 2013 ; 123 : 3117-22.
 
P.330 掲載の参考文献
1) 佐藤貴浩, 横関博雄, 片山一朗, 他. 汎発性皮膚掻痒症診療ガイドライン. 日皮会誌. 2012 ; 122 : 267-80.
 
2) 加藤則人, 大矢幸弘, 池田政憲, 他. アトピー性皮膚炎診療ガイドライン 2018. 日皮会誌. 2018 ; 128 : 2431-502.
 
3) 高山かおる, 横関博雄, 松永佳世子, 他. 接触皮膚炎診療ガイドライン 2020. 日皮会誌. 2020 ; 130 : 523-67.
 
4) 佐藤貴浩, 横関博雄, 室田浩之, 他. 皮膚掻痒症診療ガイドライン 2020. 日皮会誌. 2020 ; 130 : 1589-606.
 
5) 佐藤貴浩, 横関博雄, 室田浩之, 他. 痒疹診療ガイドライン 2020. 日皮会誌. 2020 ; 130 : 1607-26.
 
6) 佐伯秀久, 大矢幸弘, 古田淳一, 他. アトピー性皮膚炎診療ガイドライン2021. 日皮会誌. 2021 ; 131 : 2691-777.
 
7) 塩原哲夫. アトピー性皮膚炎の病因と治療. アレルギー. 2006 ; 55 : 777-80.
Medical*Online
8) 山口全一, 三宅浩行, 加藤理子. 非ステロイド性抗炎症外用剤が有効であった日光角化症の2例. 皮膚臨床. 2008 ; 50 : 1017-20.
 
9) 久保秀通, 江川清文. インドメタシン外用が奏効した日光角化症の1例. 西日皮膚. 2010 ; 72 : 36-9.
 
P.333 掲載の参考文献
1) 医薬品インタビューフォーム. 皮膚外用合成副腎皮質ホルモン・抗生物質配合剤 ベタメタゾン吉草酸エステル・ゲンタマイシン硫酸塩製剤 リンデロン(R) -VG 軟膏0.12%. 2019年4月改訂 (改訂第13版).
 
2) 小堀辰治, 木根渕承一. Betamethasone-Gentamicin 軟膏使用経験. 皮紀. 1968 ; 63 : 181-94.
 
3) 笹川正二. リンデロンVG 軟膏の使用経験とゲンタマイシンの皮表細菌数への影響について. 皮紀. 1970 ; 65 : 39-44.
 
4) Watanabe S, Ohnishi T, Yuasa A, et al. The first nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan. J Infect Chemother. 2017 ; 23 : 503-11.
PubMed
5) Nakaminami H, Noguchi N, Ikeda M, et al. Molecular epidemiology and antimicrobial susceptibilities of 273 exfoliative toxin-encoding-gene-positive Staphylococcus aureus isolates from patients with impetigo in Japan. J Med Microbiol. 2008 ; 57 : 1251-8.
PubMed
6) 高山かおる, 横関博雄, 松永佳世子, 他. 接触皮膚炎ガイドライン 2020. 日皮会誌. 2020 ; 130 : 423-567.
 
7) Pirila BV, Hirvonen ML, Rouhunkoskib S. The pattern of cross-sensitivity to neomycin. Dermatologica. 1968 ; 136 : 321-4.
 
P.335 掲載の参考文献
1) Parrado C, Mascaraque M, Gilaberte Y, et al. Fernblock (polypodium leucotomos extract) : molecular mechanisms and pleiotropic effects in light-related skin conditions, photoaging and skin cancers, a review. Int J Med Sci. 2016 ; 17 : 1026.
 
2) Parrado C, Philips N, Gilaberte Y, et al. Oral photoprotection : effective agents and potential candidates. Front Med (Lausanne). 2018 ; 5 : 188.
PubMed
3) Gonzalez S, Pathak MA, Cuevas J, et al. Topical or oral administration with an extract of polypodium leucotornos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photoderm Photoimmunol Photomed. 1997 ; 13 : 50-60.
PubMed
4) Middelkamp-Hup MA, Pathak MA, Parrado C, et al. Oral polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. Oral polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. 2004 ; 51 : 910-8.
PubMed
5) Shalka S, Vitale-Villarejo MA, Agelune CM, et al. The benefits of using a compound containing polypodium leucotomos extract for reducing erythema and pigmentation resulting from ultraviolet radiation. Surg Cosmet Dermatol. 2014 ; 6 : 344-8.
 
6) Ito N, Seki S, Ueda F. The protective role of astaxanthin for UV-induced skin deterioration in healthy people-a randomized, double-blind, placebo-controlled trial. Nutrients. 2008 ; 10 : 817.
 
7) Baswan SM, Marini A, Klosner AE, et al. Orally administered mixed carotenoids protect human skin against ultraviolet A-induced skin pigmentation : a doubleblind, placebo-controlled, randomized clinical trial. Photoderm Photoimmunol Photomed. 2020 ; 36 : 219-25.
 
P.338 掲載の参考文献
1) 佐藤健司. コラーゲン・コラーゲンペプチド. アンチ・エイジング医学. 2015 ; 11 : 81-6.
 
2) Iwai K, Hasegawa T, Taguchi Y, et al. Identification of food-delivered collagen peptides in human blood after oral ingestion of gelatin hydrolysates. J Agric Food Chem. 2005 ; 53 : 6531-6.
 
3) Shigemura Y, Iwai K, Morimatsu F, et al. Effect of polys-hydroxyproline (Pro-Hyp), a food-derivered collagen peptide in human blood, on growth of fibroblasts from mouse skin. J Agric Food Chem. 2009 ; 57 : 444-9.
 
4) Porksch E, Segger D, Degwert J, et al. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology : a double-blind, placebo-controlled study. Skin Pharmacol. 2014 ; 27 : 47-55.338
 
5) 宮永美帆, 内山太郎, 上田修. コラーゲンペプチドの肌状態改善効果. 応用薬理. 2016 ; 90 : 101-7.
Medical*Online
P.343 掲載の参考文献
1) 岩城佳津美. シワの種類と注入法. In : 宮地良樹, 他, 編. エビデンスに基づく美容皮膚科治療. 中山書店 ; 2019. p.14-22.
 
2) de Maio M. Myomodulation with injectable fillers : an innovative approach to addressing facial muscle movement. Aesth Plast Surg. 2018 ; 42 : 798-814.
 

書評

最近チェックした商品履歴

Loading...